研究者詳細

顔写真

オオコシ　アキラ
大越　明
Akira Ohkoshi
所属
大学院医学系研究科　医科学専攻　神経・感覚器病態学講座（耳鼻咽喉科・頭頸部外科学分野）（臨床）
職名
准教授
学位

  • 博士（医学） （東北大学）

e-Rad 研究者番号
70772979

経歴 10

  • 2023年11月 ～ 継続中
    東北大学　耳鼻咽喉・頭頸部外科　准教授

  • 2020年4月 ～ 2023年10月
    東北大学病院　耳鼻咽喉・頭頸部外科　講師

  • 2015年7月 ～ 2020年3月
    東北大学病院　耳鼻咽喉・頭頸部外科　助教

  • 2014年8月 ～ 2015年6月
    仙台医療センター　耳鼻咽喉科・頭頸部外科

  • 2013年4月 ～ 2014年7月
    いわき市立総合磐城共立病院　耳鼻咽喉科

  • 2008年10月 ～ 2009年3月
    東北大学病院　耳鼻咽喉・頭頸部外科　医員

  • 2007年10月 ～ 2008年9月
    仙台社会保険病院　耳鼻咽喉科

  • 2007年1月 ～ 2007年9月
    石巻赤十字病院　耳鼻咽喉科

  • 2006年4月 ～ 2006年12月
    東北大学病院　耳鼻咽喉・頭頸部外科　医員

  • 2004年5月 ～ 2006年3月
    古川市立病院　臨床研修医

︎全件表示 ︎最初の5件までを表示

学歴 2

  • 東北大学大学院医学系研究科

    2009年4月 ～ 2013年3月

  • 東北大学 医学部

    1997年4月 ～ 2004年3月

論文 127

  1. A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications

    Reina Ito, Hiroyuki Suzuki, Kenichiro Ishikawa, Kazutake Yagi, Akira Ohkoshi, Yukio Katori, Mika K. Kaneko, Yukinari Kato

    Antibodies　2026年7月

    DOI： 10.3390/antib15040059 　

  2. Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial

    Tomoya Yokota, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Ayako Nakanome, Yuji Hirayama, Naoki Nishio, Akira Ohkoshi, Kaoru Tanaka, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Akira Seto, Satoshi Kano, Takayuki Taruya, Go Omura, Junki Mizusawa, Keita Sasaki, Makoto Tahara

    Oral Oncology　177　107977-107977　2026年6月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.oraloncology.2026.107977 　

    ISSN：1368-8375

  3. Treatment and prognosis of subglottic cancers: a 10-year, multicenter, retrospective study in northern Japan. 国際誌

    Akira Ohkoshi, Katsunori Katagiri, Satoshi Kano, Kazutake Yagi, Hiroshi Idogawa, Satoshi Toyoma, Iori Kusaka, Takashi Kasai, Yukiko Saito, Kizuku Owada, Hisataka Ominato, Haruka Kaya, Eiichi Ishida, Kazuya Kurakami, Atsushi Yoshimura, Kenta Taguchi, Takuya Yoshida, Ryo Ishii, Kenjiro Higashi, Yukio Katori

    Oral oncology　179　108021-108021　2026年5月21日

    DOI： 10.1016/j.oraloncology.2026.108021 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Subglottic cancer is a rare malignancy for which limited data on its epidemiology, prognosis, recurrence, and laryngeal preservation are available. This multicenter, retrospective study aimed to elucidate the treatment outcomes of subglottic cancer compared with glottic and supraglottic cancers. MATERIAL AND METHODS: Sixty-six patients with subglottic cancer were identified among 1763 patients with laryngeal cancer treated with curative-intent surgery or (chemo)radiotherapy at 13 hospitals in northern Japan. Patients' characteristics, treatment modalities, recurrence patterns, and prognosis, including disease-free survival (DFS), overall survival (OS), disease-specific survival (DSS), and laryngeal-preservation survival (LPS), were compared across the three primary tumor subsites. Outcomes of subglottic cancer were further analyzed according to initial treatment. RESULTS: Compared with glottic and supraglottic cancers, subglottic cancer presented with more advanced T status, higher rates of total laryngectomy and recurrence, and poorer DFS, OS, DSS, and LPS. Analysis by stage indicated that subglottic cancer tended to show poorer DFS in stage III-IV cases. In subglottic cancer, (chemo)radiotherapy was effective for T1-2 disease, whereas T3-4 cases had a high local recurrence rate. Total laryngectomy provided good local control in T3-4 cases, but it was frequently followed by nodal recurrence and distant metastasis. CONCLUSION: Subglottic cancer demonstrated a more locally advanced presentation and poorer prognosis than other laryngeal subsites, a trend also observed in stage III-IV disease. Though initial surgery provided good local control in advanced subglottic cancer, it was associated with high rates of nodal recurrence and distant metastasis.

  4. Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway. 国際誌

    Ken Saijo, Hiroo Imai, Tomoyuki Iwasaki, Ryo Ishii, Kenjiro Higashi, Akira Ohkoshi, Yuto Yamazaki, Tomoaki Shirakawa, Ryo Saito, Shonosuke Wakayama, Ryunosuke Numakura, Yuya Yoshida, Sakura Taniguchi, Yuki Kasahara, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Takashi Suzuki, Yukio Katori, Chikashi Ishioka, Hisato Kawakami

    JCO precision oncology　10　(4)　e2501050　2026年4月

    DOI： 10.1200/PO-25-01050 　

    詳細を見る 詳細を閉じる

    PURPOSE: Cetuximab plus paclitaxel (CET + PTX) is frequently administered after immune checkpoint inhibitor (ICI) therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However, the relation between responses to these two treatment lines has remained unclear. We aimed to clarify this relation and its potential mechanisms, focusing on the patients treated with pembrolizumab plus chemotherapy and subsequent CET + PTX. PATIENTS AND METHODS: We retrospectively reviewed patients with R/M-HNSCC who received pembrolizumab plus chemotherapy and subsequent CET + PTX at Tohoku University Hospital between April 2020 and November 2025. Clinical outcomes of CET + PTX were assessed according to response to prior pembrolizumab plus chemotherapy. Gene expression and immunohistochemical (IHC) analyses of pretreatment tumor samples, as well as HNSCC cell-based assays, were performed. RESULTS: This study included 30 patients. The overall response rate (ORR) to subsequent CET + PTX was 57%. The ORR and progression-free survival (PFS) of CET + PTX were significantly greater in patients who showed progressive disease on pembrolizumab plus chemotherapy than in responders (P < .01). Gene expression analyses revealed enrichment of Janus kinase (JAK)-STAT signaling pathways in pembrolizumab plus chemotherapy nonresponders who responded to CET + PTX. Consistently, high tumor expression of phosphorylated STAT3 was observed exclusively in this subgroup by IHC. CET sensitivity across HNSCC cell lines correlated with STAT3 phosphorylation. CONCLUSION: Responses to pembrolizumab plus chemotherapy and subsequent CET + PTX were inversely associated in R/M-HNSCC. Activation of the JAK-STAT signaling pathway, particularly STAT3 phosphorylation, may identify tumors resistant to pembrolizumab plus chemotherapy but sensitive to CET + PTX, thereby guiding post-ICI treatment selection.

  5. Acoustic analysis in the assessment of postoperative speech impairment in oral cancer patients. 国際誌

    Yutaro Saito, Takeshi Sato, Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Ayako Nakanome, Jun Suzuki, Yukio Katori

    Oral and maxillofacial surgery　30　(1)　9-9　2025年12月20日

    DOI： 10.1007/s10006-025-01497-2 　

    詳細を見る 詳細を閉じる

    PURPOSE: Acoustic analysis is an objective and quantitative method in diagnosing speech disorders and evaluating treatment efficacy. Although many reports have used acoustic analysis for oral cancer patients, few studies have focused on the extent of tongue resection. The aim of this study was to evaluate the usefulness of acoustic analysis in the assessment of postoperative speech impairment in oral cancer patients. METHODS: Postoperative speech data as well as Speech Handicap Index (SHI) and 5-point speech intelligibility scale were collected from 65 patients including 31 cases of oral cancer resection without glossectomy, 18 cases of partial glossectomy, and 16 cases of subtotal glossectomy. Speech data were acoustically analyzed by triangular vowel space area, vowel articulation index (VAI), first (F1) and second (F2) formant slopes, and compared according to the extent of tongue resection. RESULTS: The frequency of speech impairment assessed by SHI and 5-point speech intelligibility scale was differed according to the extent of tongue resection. As acoustic analysis, VAI and F1 slope in cases of subtotal glossectomy were significantly smaller than those in cases of partial glossectomy. F2 slope in cases of subtotal glossectomy was significantly smaller than those in the other cases. CONCLUSION: Acoustic analysis was potentially useful as an objective speech assessment for the patients who underwent oral cancer surgery.

  6. Treatment outcomes of definitive radiotherapy for unresectable salivary gland cancers: a multicenter, retrospective study in northern Japan. 国際誌

    Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Tomonori Kambayshi, Satoshi Kano, Takahiro Kusaka, Daisuke Matsushita, Kosuke Murayama, Yuya Miyakura, Satoshi Kubota, Ryosuke Sato, Shino Godo, Hiroki Tomizawa, Satoshi Toyoma, Ai Tagawa, Akina Shirotori, Yukio Katori

    Japanese journal of clinical oncology　55　(12)　1342-1348　2025年12月3日

    DOI： 10.1093/jjco/hyaf147 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Treatment of unresectable salivary gland cancers is challenging. This multicenter, retrospective study aimed to evaluate the treatment outcomes of definitive radiotherapy, with or without chemotherapy, for locally advanced, unresectable, salivary gland cancers. METHODS: A total of 27 patients with unresectable salivary gland cancers who underwent concurrent chemoradiotherapy or radiotherapy with curative intent between 2012 and 2022 at 13 hospitals in northern Japan were included in this study. Overall survival (OS) and progression-free survival (PFS) were assessed, and factors affecting OS and PFS were identified through univariate and multivariate Cox regression analyses. The variables evaluated included age, sex, primary site, histological type, clinical T and N status, clinical stage, treatment type, and radiation type. RESULTS: Seven patients received concurrent chemoradiotherapy, and 20 patients received radiotherapy (6 photon, 11 proton, 3 heavy ion). With a median follow-up period of 28 months, the three-year OS and PFS rates for the 27 patients were 54.4% and 27.8%, respectively. Patients who received concurrent chemoradiotherapy had better PFS than those who received radiotherapy alone (HR 0.16, 95% CI 0.03-0.81, P = .026). CONCLUSIONS: Definitive radiotherapy for locally advanced, unresectable, salivary gland cancers resulted in relatively good outcomes. Concurrent chemoradiotherapy was associated with better PFS than radiotherapy.

  7. Cisplatin-induced genetic alterations in KEAP1 promote therapeutic resistance in head and neck squamous cell carcinoma. 国際誌

    Yuki Nakayama, Keiko Taguchi, Shun Wakamori, Akira Uruno, Akihito Otsuki, Akira Ohkoshi, Hidekazu Shirota, Tomoyuki Iwasaki, Yukio Katori, Masayuki Yamamoto

    Redox biology　86　103819-103819　2025年10月

    DOI： 10.1016/j.redox.2025.103819 　

    詳細を見る 詳細を閉じる

    Cisplatin (CDDP) resistance remains a major challenge in the treatment of recurrent head and neck squamous cell carcinoma (HNSCC). The KEAP1-NRF2 system, a central regulator of cellular redox homeostasis, is frequently altered in cancer, but its contribution to acquired CDDP resistance in HNSCC remains to be clarified. To address this, we investigated NRF2 activation in CDDP resistance using seven parental (P) HNSCC cell lines and their CDDP-resistant (CR) derivatives. Among these P-CR pairs, three CR lines exhibited elevated NRF2 expression; two harbored KEAP1 mutations, and one had an NFE2L2 mutation that were present in both P and CR lines. These NRF2-high CR lines showed upregulation of NRF2 target genes and enrichment of xenobiotic metabolism and reactive oxygen species pathways. Mitomycin C (MMC), a cytotoxic agent for its synthetic lethality in NRF2-activated cancer cells, demonstrated strong cytotoxicity specifically in these NRF2-high CR lines. Immunohistochemical analysis on clinical samples found that high NRF2 expression was significantly associated with poor prognosis and was frequently observed in recurrent tumors following chemoradiotherapy with CDDP. These results suggest that CDDP therapy, while initially effective, may paradoxically promote tumor progression and therapeutic resistance by aberrantly activating the KEAP1-NRF2 axis. This redox-driven adaptation highlights a critical characteristic in NRF2-hyperactivated HNSCC that is exploitable by MMC treatment.

  8. Practical pathological methods for reliable diagnosis of secretory carcinomas of the salivary gland. 国際誌

    Ryo Kawaura, Tomohiko Ishikawa, Hirofumi Shibata, Masashi Kuroki, Kazuhiro Kobayashi, Yuki Hanamatsu, Tatsuhiko Miyazaki, Hiroyuki Tomita, Takuma Ishihara, Hajime Usubuchi, Yayoi Aoyama, Yukinori Asada, Takayuki Imai, Akira Ohkoshi, Akira Hara, Yukio Katori, Toru Furukawa, Takenori Ogawa

    Discover oncology　16　(1)　1254-1254　2025年7月3日

    DOI： 10.1007/s12672-025-03072-3 　

    詳細を見る 詳細を閉じる

    Secretory carcinomas (SCs) of the salivary gland have recently been recognized as low-grade, malignant tumors. Before this designation, most SCs were diagnosed as variants of acinic cell carcinomas (AciCCs). SCs harbor the t(12;15)(p13;q25) translocation that generates an oncogenic fusion gene, ETS variant transcription factor 6/Neurotrophic tyrosine receptor kinase(ETV6::NTRK3). However, detecting fusion genes in a clinical setting is time-consuming and costly. In this study, we examined 31 cases previously diagnosed as AciCC and SC using pathological analyses with detection of fusion genes using ETV6 break-apart fluorescence in-situ hybridization and reverse transcription-polymerase chain reaction. After re-analysis, we found that these 31 cases actually comprised 21 SCs and 10 AciCCs. We examined the diagnostic utility of immunohistochemistry by comparing results with the fusion gene, Pan-Trk, which despite having recently been reported as effective for diagnosis of SC, was not universally accurate. However, combining mammaglobin and S-100 could be particularly useful in diagnosing SC. This practical method will contribute to accurate diagnosis of SCs, while saving time in daily clinical practice.

  9. Prognostic factors and overall survival for recurrent and metastatic head and neck squamous cell carcinoma: a multicenter retrospective analysis

    Kazufumi Obata, Satoshi Kano, Akira Ohkoshi, Akito Kakiuchi, Takahiro Inoue, Jun Taguchi, Ai Tagawa, Daisuke Matsushita, Jun Miyaguchi, Tentaro Endo, Ryo Ishii, Kazue Ito, Eiichi Ishida, Takahiro Suzuki, Naoto Araki, Tomotaka Kawase, Kenichi Takano

    Japanese Journal of Clinical Oncology　55　(9)　1013-1021　2025年5月28日

    出版者・発行元： Oxford University Press (OUP)

    DOI： 10.1093/jjco/hyaf088 　

    eISSN：1465-3621

    詳細を見る 詳細を閉じる

    Abstract Background Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, some patients remain unresponsive to treatment, necessitating further investigation into optimal therapeutic strategies and prognostic biomarkers. This study aimed to evaluate the efficacy of various therapies and identify factors influencing overall survival (OS) in these patients. Methods We retrospectively analyzed 606 patients (517 men, 89 women; median age 68 years) treated at 13 head and neck cancer specialty facilities in Japan between January 2018 and December 2022. Associations between OS and variables, including age, sex, primary site, Eastern Cooperative Oncology Group performance status, estimated glomerular filtration rate, therapeutic target lesion, history of drug use in systemic chemotherapy, number of treatment lines, nondrug treatments, de novo metastasis, programmed death-ligand 1 combined positive score, and platinum resistance were statistically examined. Results Median OS was 14.2 months, and median progression-free survival was 5.0 months. Multivariate analysis identified poor OS in patients with oral cavity tumors and performance status 2–3, whereas ICI therapy and nondrug salvage interventions were associated with improved OS. ICI/non-ICI subgroup analysis revealed that ICI may have a limited effect on oral cancer. Additionally, our results indicated that a history of platinum therapy for R/M HNSCC may not affect the therapeutic efficacy of ICIs. Conclusion For patients with R/M HNSCC, further OS improvement may be achieved using ICIs or aggressive nondrug salvage therapy and by considering the use of chemotherapy other than ICI for patients with oral cancer or poor PS.

  10. 北日本13施設における再発転移頭頸部癌に対する化学療法の原発部位別の治療効果の検討

    荒木 直人, 千田 邦明, 倉上 和也, 八鍬 修一, 小幡 和史, 加納 里志, 大越 明, 垣内 晃人, 井上 貴博, 田口 純, 田川 愛, 松下 大佑, 宮口 潤, 遠藤 天太郎, 石井 亮, 石田 英一, 鈴木 貴博, 川瀬 友貴, 伊藤 吏

    頭頸部癌　51　(2)　179-179　2025年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  11. 全ゲノム解析を用いた高感度MRD解析の早期再発検出における有用性 MONSTAR-SCREEN-3研究中間解析

    秋定 直樹, 藤澤 孝夫, 橋本 直佳, 中村 能章, 小林 信, 沖 英次, 岡野 晋, 本間 明宏, 対馬 那由多, 大越 明, 石井 亮, 長岡 真人, 福里 壮一朗, 小川 武則, 柴田 博史, 坂東 英明, 吉野 孝之, 松浦 一登

    頭頸部癌　51　(2)　218-218　2025年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  12. Endoscopic-Assisted Tonsillectomy With Preemptive Hemostasis and Low-Output Bipolar Energy: A Strategy to Reduce Postoperative Hemorrhage. 国際誌

    Haruka Ota, Takuya Yoshida, Keita Suzuki, Kazutake Yagi, Kenjiro Higashi, Akira Ohkoshi, Yukio Katori

    Cureus　17　(5)　e84933　2025年5月

    DOI： 10.7759/cureus.84933 　

    詳細を見る 詳細を閉じる

    Introduction Tonsillectomy is a common surgical procedure in otolaryngology; however, postoperative hemorrhage remains a serious complication. Although novel hemostatic devices have been introduced, no definitive preventive strategy has been established. This study evaluated a standardized surgical approach combining preemptive hemostasis, reduced energy device output, and endoscopic assistance to minimize postoperative complications. Methods This single-center, non-randomized, observational cohort study included 137 patients aged 15 years or older who underwent extracapsular tonsillectomy between April 2018 and March 2025. Patients were grouped based on the time period of treatment: those who underwent conventional tonsillectomy between 2018 and 2021 comprised the Conventional Group (n = 85), and those who underwent a standardized procedure incorporating preemptive hemostasis and low-output energy devices between 2022 and 2025 comprised the Standardized Group (n = 52). Perioperative outcomes, postoperative hemorrhage rates, pain control, and hospital stay length were compared between groups using the Mann-Whitney U test and Fisher's exact test (p < 0.05 was considered significant). Results The Standardized Group showed a significantly lower postoperative hemorrhage rate (0% vs. 9.5%, p = 0.0236) and less intraoperative blood loss (0.42 ± 1.01 mL vs. 8.31 ± 26.7 mL, p = 0.0031) compared to the Conventional Group. Although operative time was longer (83.5 ± 33.3 min vs. 56.5 ± 23.8 min, p < 0.001), the Standardized Group had a shorter hospital stay (8.86 ± 1.24 days vs. 10.1 ± 1.15 days, p < 0.001) and required fewer rescue analgesic interventions (p = 0.0178). Conclusion The combination of preemptive hemostasis, reduced energy output, and endoscopic supervision significantly improved surgical outcomes, reduced complications, and enhanced the educational experience for junior surgeons. This protocol represents a standardized, cost-effective technique that enhances safety and surgical training.

  13. 鼻副鼻腔癌に対するTPF併用化学放射線療法についての検討

    登米 慧, 大越 明, 東 賢二郎, 石井 亮, 橋本 光, 大井 康平, 香取 幸夫

    日本耳鼻咽喉科頭頸部外科学会会報　128　(4)　654-654　2025年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  14. Locally advanced maxillary sinus cancer fed from the internal carotid artery. 国際誌

    Tatsuhiko Yamada, Masashi Kuroki, Hirofumi Shibata, Shoma Nagata, Hiroshi Kawada, Hiroki Kato, Akira Ohkoshi, Ikuho Kojima, Ryota Iinuma, Hiroshi Okuda, Yukio Katori, Masayuki Matsuo, Takenori Ogawa

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery　2025年3月28日

    DOI： 10.1007/s00405-025-09343-7 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: Superselective intra-arterial infusion of cisplatin and concomitant radiation therapy (RADPLAT) is one of the effective treatments for advanced maxillary sinus cancer, and prospective trials have been conducted. However, treatment of cases with intraorbital infiltration or skull base infiltration that are fed from the internal carotid artery (ICA) may be problematic. In this study, we investigated the frequency, treatment, and prognosis of locally advanced maxillary sinus cancer fed from the ICA. METHOD: This study included patients with locally advanced maxillary sinus cancer (clinical T4a or T4b) who underwent RADPLAT only via external carotid artery from January 2008 to January 2024. RESULT: Nineteen of 44 cases were fed from the ICA (43.2%). Three-year overall survival (OS), three-year progression-free survival (PFS), and three-year local control rate (LCR) of all cases were 69.8%, 47.5%, and 61.8%, respectively. The three-year OS, PFS and LCR were equivalent between cases with or without feeding from the ICA. CONCLUSION: This study revealed the frequency and prognosis of locally advanced maxillary sinus cancer fed from the ICA. The prognosis was equivalent between cases with or without feeding from the ICA; therefore, it would be considered important to determine the tumor volume for each feeding blood vessel and assess the areas of dual perfusion.

  15. Sensorineural hearing loss after concurrent chemoradiotherapy with high-dose cisplatin in head and neck cancer patients: Roles of nutrition and trace elements. 国際誌

    Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Satoshi Toyoma, Tadahisa Shishido, Takaya Yamamoto, Hinako Harada, Ayako Nakanome, Yukio Katori

    Auris, nasus, larynx　52　(2)　141-145　2025年2月5日

    DOI： 10.1016/j.anl.2025.01.013 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: Sensorineural hearing loss (SNHL) is one of the most important adverse events of concurrent chemoradiotherapy (CCRT) with high-dose cisplatin for locally advanced head and neck squamous cell carcinoma (HNSCC). This retrospective study aimed to elucidate the effects of nutritional status and trace elements on the development of SNHL. METHODS: A retrospective review of 211 ears from 109 patients with HNSCC who underwent CCRT with high-dose cisplatin was performed. SNHL of each ear was classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and possible contributing factors were evaluated by univariate and multivariate analyses. Age, sex, primary site, clinical stage, treatment intent, smoking and drinking habits, history of hypertension, diabetes mellitus, body mass index, serum albumin, trace elements (Fe, Zn, Cu, Se), pretreatment average hearing level at 2-8 kHz, weight loss rate, cumulative cisplatin dose, and inner ear radiation dose were the variables evaluated. RESULTS: Ordinal logistic regression analysis showed that increased age, better pretreatment average hearing level at 2-8 kHz, and cumulative cisplatin dose were independent factors associated with the development of SNHL. CONCLUSION: Nutritional status and trace elements were not associated with the development of SNHL caused by CCRT with high-dose cisplatin.

  16. CT scoring system for differentiating of sinonasal inverted papilloma and squamous cell carcinoma arising from inverted papilloma. 国際誌

    Miki Umeda, Masashi Kuroki, Hiroki Kato, Hirofumi Shibata, Nansei Yamada, Hiroshi Okuda, Kosuke Terazawa, Ryota Iinuma, Akira Ohkoshi, Shun Wakamori, Ikuho Kojima, Yukio Katori, Masayuki Matsuo, Takenori Ogawa

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery　2024年12月12日

    DOI： 10.1007/s00405-024-09107-9 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: To distinguish squamous cell carcinoma in inverted papilloma (IP-SCC) from IP, the utility of CT scoring system was investigated. METHODS: We extracted cases histopathologically diagnosed with IP and IP-SCC of the sinonasal cavity from June 2004 to May 2021. Preoperative unenhanced CT images were used to evaluate the presence or absence of bone destruction and erosion: Score 1 = positive for bone destruction and/or erosion; Score 0 = negative for bone destruction and erosion. The CT scores in 10 sites of the sinonasal cavity and their adjacent areas were calculated. RESULTS: Fifty-six cases of IP and 20 cases of IP-SCC were enrolled in this study. Bone destruction and/or erosion was more frequently observed in IP-SCC than in IP at the sites of the skull base (p = 0.0001), orbital wall (p < 0.0001), maxillary sinus (p < 0.0001), nasal septum (p < 0.0001), inferior nasal concha (p = 0.0046), ethmoid sinus (p < 0.0001), pterygoid process (p = 0.0031), and frontal sinus (p = 0.0009). The total CT scores at the 10 sites for diagnosing IP-SCC had sensitivity and specificity of 70% and 87.5% (AUC: 0.810, p < 0.001); furthermore, those at the eight sites excluding fontanelle and middle nasal concha improved sensitivity and specificity of 75% and 83.9% (optimal threshold of 2, AUC: 0.862, p < 0.001). CONCLUSION: The CT scoring system evaluating bone destruction and erosion could accurately differentiate IP-SCC from IP.

  17. Predictors of recurrence and survival after salivary gland cancer surgery: A multicenter, retrospective study in northern Japan. 国際誌

    Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Tadahisa Shishido, Satoshi Kano, Takahiro Kusaka, Daisuke Matsushita, Kosuke Murayama, Yuya Miyakura, Satoshi Kubota, Ryosuke Sato, Shino Godo, Hiroki Tomizawa, Satoshi Toyoma, Ai Tagawa, Akina Shirotori, Yukio Katori

    Oral oncology　160　107131-107131　2024年12月2日

    DOI： 10.1016/j.oraloncology.2024.107131 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Salivary gland cancer is a rare disease composed of more than 20 histological types with different grades of malignancy. The aim of this multicenter, retrospective study was to identify the most important predictors affecting recurrence and survival after surgery. MATERIAL AND METHODS: A total of 543 patients with salivary gland cancers that underwent curative surgery between 2012 and 2022 in 13 institutions in northern Japan were evaluated in this study. Predictors affecting recurrence and survival were identified by univariate and multivariate Cox regression analyses. Age, sex, primary site, histological type, pathological T status, surgical margin, lymph node metastasis, extranodal extension, and postoperative radiotherapy were the variables evaluated. RESULTS: Multivariate Cox regression analysis showed that increasing age, submandibular cancer, pathological T status 3 or 4, positive surgical margin, and lymph node metastasis, especially with extranodal extension, were independent risk factors for both recurrence and survival. Sublingual cancer was an independent risk factor for recurrence. Postoperative radiotherapy was associated with a lower risk of recurrence and a good prognosis, and adenoid cystic carcinoma was associated with a good prognosis. CONCLUSION: Lymph node metastasis with extranodal extension was the most important prognostic factor affecting both recurrence and survival after surgery, adenoid cystic carcinoma was associated with a good prognosis, and postoperative radiotherapy was associated with a lower risk of recurrence and a good prognosis.

  18. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck. 国際誌

    Kazuki Yokoyama, Koichiro Wasano, Keita Sasaki, Ryunosuke Machida, Mitsuhiko Nakahira, Koji Kitamura, Tomofumi Sakagami, Naohiro Takeshita, Akira Ohkoshi, Motoyuki Suzuki, Ichiro Tateya, Yohei Morishita, Mariko Sekimizu, Masahiro Nakayama, Taiji Koyama, Hirofumi Shibata, Satoru Miyamaru, Naomi Kiyota, Nobuhiro Hanai, Akihiro Homma

    Japanese journal of clinical oncology　54　(10)　1115-1122　2024年10月3日

    DOI： 10.1093/jjco/hyae117 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan. METHODS: From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied. RESULTS: The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens' first-month costs were 612 851-849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000-800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN. CONCLUSION: First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.

  19. Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008. 国際誌

    Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Hirokazu Uemura, Kiyoto Shiga, Mitsuhiko Nakahira, Takahiro Asakage, Yuki Saito, Keita Sasaki, Ryo Kitabayashi, Satoshi Ishikura, Yasumasa Nishimura, Makoto Tahara

    Oral oncology　157　106976-106976　2024年10月

    DOI： 10.1016/j.oraloncology.2024.106976 　

    詳細を見る 詳細を閉じる

    BACKGROUND AND PURPOSE: Hypothyroidism is a recognized late adverse event following radiotherapy for head and neck cancer (HNC). In the JCOG1008 trial, we treated patients with high-risk HNC with postoperative chemoradiotherapy. We aimed to elucidate factors associated with hypothyroidism by analyzing the JCOG1008 data. MATERIALS AND METHODS: In 2012-2018, 261 patients from 28 institutions were enrolled in JCOG1008. Thyroid function tests were conducted to assess hypothyroidism, including free thyroxine (FT4) and thyroid-stimulating hormone assays. Hypothyroidism was defined as Grade 2 or higher in CTCAE v4.0. Various clinical and dosimetric parameters were analyzed. In radiotherapy, there were no dose constraints for the thyroid. Multivariable analysis was conducted on these variables to identify predictive factors for hypothyroidism. RESULTS: The analysis included 162 patients (57 with 3D-CRT and 105 with IMRT), with a median follow-up of 4.7 years (0.3-9.3 years). Among these, 27 (16.7 %) developed hypothyroidism within 2 years after radiotherapy. In a multivariable analysis, the weekly cisplatin [OR=7.700 (CI: 1.632-36.343, p = 0.010)] and baseline FT4 [OR=0.009 (CI: <0.001-0.313, p = 0.010)] were significantly associated with hypothyroidism in the IMRT group. Regarding dosimetric characteristics, V60Gy [OR=1.069 (CI: 0.999-1.143, p = 0.054)] was potentially associated with the development of hypothyroidism. CONCLUSION: The study revealed that the incidence of hypothyroidism within 2 years after postoperative chemoradiotherapy for high-risk HNC was 16.7 % based on analytical results from prospective clinical trials.

  20. Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008. 国際誌

    Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma

    Cancer medicine　13　(18)　e70235　2024年9月

    DOI： 10.1002/cam4.70235 　

    詳細を見る 詳細を閉じる

    BACKGROUND: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non-inferior to 3-weekly cisplatin (100 mg/m2) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS). METHODS: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5-fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log-rank test. RESULTS: The total incidence of AKI was lower in the weekly arm than in the 3-weekly arm (38/122 [31.1%] vs. 56/129 [43.4%]). Additionally, stage II/III AKI occurred less frequently in the weekly arm than in the 3-weekly arm (8/122 [6.6%] vs. 19/129 [14.7%]). Cisplatin doses were similar in the weekly arm for patients with and without AKI (median, 238.6 mg/m2 vs. 239.2 mg/m2; p = 0.94), but lower in the 3-weekly arm for those who developed AKI (median, 276.3 mg/m2 vs. 297.4 mg/m2; p = 0.007). In the weekly arm, there was no difference in OS between patients with and without AKI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.53 to 2.10). However, in the 3-weekly arm, patients with AKI had poorer OS than those without AKI (HR, 1.83; 95% CI, 1.04 to 3.21). CONCLUSIONS: In this supplementary analysis of JCOG1008 data, AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3-weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 in this setting.

  21. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas

    Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, Guanjie Li, Tomohiro Tanaka, Manabu Kawada, Akira Ohkoshi, Mika K. Kaneko, Yukio Katori, Yukinari Kato

    International Journal of Molecular Sciences　25　(17)　9190-9190　2024年8月24日

    出版者・発行元： MDPI AG

    DOI： 10.3390/ijms25179190 　

    eISSN：1422-0067

    詳細を見る 詳細を閉じる

    CD44 regulates cell adhesion, proliferation, survival, and stemness and has been considered a tumor therapy target. CD44 possesses the shortest CD44 standard (CD44s) and a variety of CD44 variant (CD44v) isoforms. Since the expression of CD44v is restricted in epithelial cells and carcinomas compared to CD44s, CD44v has been considered a promising target for monoclonal antibody (mAb) therapy. We previously developed an anti-CD44v10 mAb, C44Mab-18 (IgM, kappa), to recognize the variant exon 10-encoded region. In the present study, a mouse IgG2a version of C44Mab-18 (C44Mab-18-mG2a) was generated to evaluate the antitumor activities against CD44-positive cells compared with the previously established anti-pan CD44 mAb, C44Mab-46-mG2a. C44Mab-18-mG2a exhibited higher reactivity compared with C44Mab-46-mG2a to CD44v3–10-overexpressed CHO-K1 (CHO/CD44v3–10) and oral squamous cell carcinoma cell lines (HSC-2 and SAS) in flow cytometry. C44Mab-18-mG2a exerted a superior antibody-dependent cellular cytotoxicity (ADCC) against CHO/CD44v3–10. In contrast, C44Mab-46-mG2a showed a superior complement-dependent cytotoxicity (CDC) against CHO/CD44v3–10. A similar tendency was observed in ADCC and CDC against HSC-2 and SAS. Furthermore, administering C44Mab-18-mG2a or C44Mab-46-mG2a significantly suppressed CHO/CD44v3–10, HSC-2, and SAS xenograft tumor growth compared with the control mouse IgG2a. These results indicate that C44Mab-18-mG2a could be a promising therapeutic regimen for CD44v10-positive tumors.

  22. 経口的鏡視下手術を応用した喉頭温存・下咽頭部分切除・再建手術の一例

    大越 明, 石井 亮, 香取 幸夫

    口腔・咽頭科　37　(3)　222-222　2024年8月

    出版者・発行元： 日本口腔・咽頭科学会

    ISSN：0917-5105

    eISSN：1884-4316

  23. アンドロゲン受容体(AR)陽性唾液腺癌に対するAR阻害薬Darolutamide(ODM-201)の第II相試験:単剤パート

    大塚 倫之, 岡野 晋, 今村 善宣, 瓜生 英興, 大越 明, 佐野 大佑, 塚原 清彰, 大野 十央, 花澤 豊行, 加納 里志, 西尾 直樹, 長岡 真人, 長尾 俊孝, 久野 博文, 尾尻 博也, 齋藤 尚子, 篠田 覚, 三角 俊裕, 清田 尚臣, 田原 信

    頭頸部癌　50　(2)　138-138　2024年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  24. [ANL Secondary Publication] 頭頸部がん治療が副鼻腔陰影に与える影響

    逸見 朋隆, 鈴木 淳, 石井 亮, 池田 怜吉, 小林 祐太, 生島 寛享, 野村 和弘, 菅原 充, 大越 明, 香取 幸夫

    日本耳鼻咽喉科頭頸部外科学会会報　127　(5)　689-691　2024年5月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  25. 高用量シスプラチン同時併用化学放射線治療による聴力障害

    大越 明, 東 賢二郎, 石井 亮, 香取 幸夫

    頭頸部癌　50　(2)　148-148　2024年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  26. 姑息的放射線治療が奏功した喉頭摘出拒否の高齢者下咽頭進行癌の3症例

    石井 亮, 東 賢二郎, 宍戸 雅悠, 大越 明, 香取 幸夫

    頭頸部癌　50　(2)　207-207　2024年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  27. アンドロゲン受容体(AR)陽性唾液腺癌に対するAR阻害薬Darolutamide(ODM-201)の第II相試験:単剤パート

    大塚 倫之, 岡野 晋, 今村 善宣, 瓜生 英興, 大越 明, 佐野 大佑, 塚原 清彰, 大野 十央, 花澤 豊行, 加納 里志, 西尾 直樹, 長岡 真人, 長尾 俊孝, 久野 博文, 尾尻 博也, 齋藤 尚子, 篠田 覚, 三角 俊裕, 清田 尚臣, 田原 信

    頭頸部癌　50　(2)　138-138　2024年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  28. [ANL Secondary Publication] 頭頸部がん治療が副鼻腔陰影に与える影響

    逸見 朋隆, 鈴木 淳, 石井 亮, 池田 怜吉, 小林 祐太, 生島 寛享, 野村 和弘, 菅原 充, 大越 明, 香取 幸夫

    日本耳鼻咽喉科頭頸部外科学会会報　127　(5)　689-691　2024年5月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  29. Treatment of elderly patients with head and neck cancer in an aging society: Focus on geriatric assessment and surgical treatment. 国際誌

    Ryo Ishii, Akira Ohkoshi, Yukio Katori

    Auris, nasus, larynx　51　(4)　647-658　2024年4月16日

    DOI： 10.1016/j.anl.2024.04.005 　

    詳細を見る 詳細を閉じる

    Previous studies of the treatment of elderly head and neck cancer (HNC) patients were very limited and sometimes controversial. Although conclusions differ across various reports, it is often concluded that advanced chronological age does not directly affect prognosis, but that comorbidities and declines in physical and cognitive functions promote the occurrence of adverse events, especially with surgical treatment. Geriatric assessment (GA) and its screening tools are keys to help us understand overall health status and problems, predict life expectancy and treatment tolerance, and to influence treatment choices and interventions to improve treatment compliance. In addition, personal beliefs and values play a large role in determining policies for HNC treatment for elderly patients, and a multidisciplinary approach is important to support this. In this review, past research on HNC in older adults is presented, and the current evidence is explained, focusing on the management of elderly HNC patients, with an emphasis on the existing reports on each treatment stage and modality, especially the surgical procedures.

  30. 局所進行上顎洞癌に対する超選択的動注と放射線同時併用療法(JCOG1212試験) 有効性検証(T4aN0M0)の結果

    本間 明宏, 三上 剛史, 松浦 一登, 鬼丸 力也, 吉田 大介, 四宮 弘隆, 大越 明, 林 隆一, 齊藤 祐毅, 立花 弘之, 水澤 純基, 中村 健一, 福田 治彦

    日本インターベンショナルラジオロジー学会雑誌　39　(Suppl.)　182-182　2024年4月

    出版者・発行元： (一社)日本インターベンショナルラジオロジー学会

    ISSN：1340-4520

    eISSN：2185-6451

  31. Antitumor activities of anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer

    Ishikawa, K., Suzuki, H., Ohishi, T., Nakamura, T., Yanaka, M., Li, G., Tanaka, T., Ohkoshi, A., Kawada, M., Kaneko, M.K., Katori, Y., Kato, Y.

    Oncology Reports　52　(5)　2024年

    DOI： 10.3892/or.2024.8806 　

    ISSN：1791-2431 1021-335X

  32. Endothelium-Derived Extracellular Vesicles Expressing Intercellular Adhesion Molecules Reflect Endothelial Permeability and Sepsis Severity

    Takei, Y., Yamada, M., Saito, K., Kameyama, Y., Aihara, T., Iwasaki, Y., Murakami, T., Kaiho, Y., Ohkoshi, A., Konno, D., Shiga, T., Takahashi, K., Ikumi, S., Toyama, H., Ejima, Y., Yamauchi, M.

    Anesthesia and Analgesia　139　(2)　2024年

    DOI： 10.1213/ANE.0000000000006988 　

    ISSN：1526-7598 0003-2999

  33. Multiple Buttresses Reconstruction of Maxilla with Fibular Flap Using Computer-aided Design/Computer-aided Manufacturing after Maxillectomy

    Kurosawa, K., Sato, N., Ohkoshi, A., Harata, T., Ishi, S., Hayashi, M., Imai, T., Takamura, N., Matsunaga, H., Imai, Y.

    Plastic and Reconstructive Surgery - Global Open　12　(6)　2024年

    DOI： 10.1097/GOX.0000000000005914 　

    ISSN：2169-7574

  34. Dose-Finding and Efficacy Confirmation Trial of the Superselective Intra-arterial Infusion of Cisplatin and Concomitant Radiation Therapy for Locally Advanced Maxillary Sinus Cancer (JCOG1212): Results of the Efficacy Confirmation Phase in Patients with T4aN0M0

    Homma, A., Mikami, M., Matsuura, K., Onimaru, R., Yoshida, D., Shinomiya, H., Ohkoshi, A., Hayashi, R., Saito, Y., Tachibana, H., Shiga, K., Ueda, T., Uemura, H., Nakamura, K., Fukuda, H.

    International Journal of Radiation Oncology Biology Physics　118　(5)　2024年

    DOI： 10.1016/j.ijrobp.2023.11.031 　

    ISSN：1879-355X 0360-3016

  35. Breathing-Swallowing discoordination after definitive chemoradiotherapy for head and neck cancers is associated with aspiration pneumonia. 国際誌

    Takuya Yoshida, Naomi Yagi, Takenori Ogawa, Ayako Nakanome, Akira Ohkoshi, Yukio Katori, Yoshitaka Oku

    PloS one　19　(7)　e0305560　2024年

    DOI： 10.1371/journal.pone.0305560 　

    詳細を見る 詳細を閉じる

    PURPOSE: Swallowing dysfunction and the risk of aspiration pneumonia are frequent clinical problems in the treatment of head and neck squamous cell carcinomas (HNSCCs). Breathing-swallowing coordination is an important factor in evaluating the risk of aspiration pneumonia. To investigate breathing-swallowing discoordination after chemoradiotherapy (CRT), we monitored respiration and swallowing activity before and after CRT in patients with HNSCCs. METHODS: Non-invasive swallowing monitoring was prospectively performed in 25 patients with HNSCCs treated with CRT and grade 1 or lower radiation-induced dermatitis. Videoendoscopy, videofluoroscopy, Food Intake LEVEL Scale, and patient-reported swallowing difficulties were assessed. RESULTS: Of the 25 patients selected for this study, four dropped out due to radiation-induced dermatitis. The remaining 21 patients were analyzed using a monitoring system before and after CRT. For each of the 21 patients, 405 swallows were analyzed. Swallowing latency and pause duration after the CRT were significantly extended compared to those before the CRT. In the analysis of each swallowing pattern, swallowing immediately followed by inspiration (SW-I pattern), reflecting breathing-swallowing discoordination, was observed more frequently after CRT (p = 0.0001). In 11 patients, the SW-I pattern was observed more frequently compared to that before the CRT (p = 0.00139). One patient developed aspiration pneumonia at 12 and 23 months after the CRT. CONCLUSION: The results of this preliminary study indicate that breathing-swallowing discoordination tends to increase after CRT and could be involved in aspiration pneumonia. This non-invasive method may be useful for screening swallowing dysfunction and its potential risks.

  36. Clinical characteristics and outcomes of persistent bacteremia in patients with head and neck cancer in a tertiary care hospital. 国際誌

    Shiori Kitaya, Hajime Kanamori, Ryo Ishii, Makoto Katsumi, Ryoukichi Ikeda, Kenjiro Higashi, Risako Kakuta, Akira Ohkoshi, Yukio Katori

    Frontiers in medicine　11　1406983-1406983　2024年

    DOI： 10.3389/fmed.2024.1406983 　

    詳細を見る 詳細を閉じる

    INTRODUCTION: Compared to other cancers, research on bloodstream infection in head and neck cancer is scarce, lacking comparative studies on persistent versus transient bacteremia outcomes. METHODS: This retrospective survey examined patients with head and neck cancer undergoing blood culture at our center from June 2009 to May 2023. Blood culture-positive cases suspected of infection were divided into persistent bacteremia and transient bacteremia groups. We investigated their clinical, epidemiological, and microbiological features, including risk factors for persistent bacteremia and mortality. The primary outcome was 90-day mortality. RESULTS: In this 97-patient cohort, 14 (14%) cases were assigned to the persistent bacteremia group. Catheter-related bloodstream infections were the leading cause of infection in both groups, consistently contributing to a high proportion of overall bloodstream infections. The mortality rate was generally higher in the persistent bacteremia group than in the transient bacteremia group (odds ratio [OR], 2.6; 95% confidence interval [CI], 0.6-11.1), particularly in the non-clearance subgroup (OR, 9; 95% CI, 0.5-155.2). Pyogenic spondylitis was a key risk factor for persistent bacteremia, while hypoalbuminemia increased mortality. CONCLUSION: In patients with bacteremia and head and neck cancer, persistent bacteremia was associated with higher mortality than was transient bacteremia. Adittionally, bacteremia clearance in persistent bacteremia is thus crucial for prognostic improvement.

  37. Imaging findings of arrested pneumatisation and differentiation from other skull base lesions. 国際誌

    Ikuho Kojima, Yusuke Shimada, Naoko Watanabe, Kentaro Takanami, Yohei Morishita, Akira Ohkoshi, Masahiro Iikubo

    Dento maxillo facial radiology　52　(8)　20230297-20230297　2023年11月

    DOI： 10.1259/dmfr.20230297 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Arrested pneumatisation (AP) is an anatomic variant of the sphenoid sinus. Since AP remains underrecognised, otolaryngologists and radiologists may mistake AP for a lesion and perform follow-up imaging studies. We investigated the imaging findings of CT, MRI, and F-18 fludeoxyglucose (FDG)-positron emission tomography (PET) for AP, and discussed the differences between AP and other skull base lesions. METHODS: We reviewed multidetector low CT imaging of 442 patients (285 men and 157 women; age range, 19-93 years; mean age, 67.8 years) who underwent FDG-PET/CT for head and neck tumours between January 2019 and December 2019. The imaging findings of AP were reviewed on CT, MRI, FDG-PET/CT, and compared with those of fibrous dysplasia, chordoma, chondrosarcoma, multiple myeloma, and bone invasion of nasopharyngeal carcinoma. RESULTS: AP was identified in 22 patients (14 men and 8 women; age range, 24-93 years; mean age, 67.0 years) based on criteria from previous reports. AP manifested with well-circumscribed sclerotic margins on CT, without evidence of expansion. AP showed high-signal intensity on T1-/T2 weighted MRI. FDG-PET revealed non-significant uptake [maximum standardised uptake value (SUVmax): 0.85 (range, 0.4-1.27)] in AP. Contrastingly, skull base lesions showed expansion, poorly circumscribed boundaries without osteosclerotic margins, and moderate-to-severe FDG uptake (SUVmax: 1.8-8.4). CONCLUSIONS: The characteristic imaging findings of AP, namely non-expansile on CT and non-uptake on FDG-PET, may aid in its differentiation from other skull base lesions.

  38. Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials. 国際誌

    Tomohiko Ishikawa, Takenori Ogawa, Masahiro Shiihara, Hajime Usubuchi, Yuko Omori, Katsuya Hirose, Taito Itoh, Takuya Yoshida, Ayako Nakanome, Akira Okoshi, Kenjiro Higashi, Ryo Ishii, Masahiro Rokugo, Shun Wakamori, Yasunobu Okamura, Kengo Kinoshita, Yukio Katori, Toru Furukawa

    iScience　26　(5)　106695-106695　2023年5月19日

    DOI： 10.1016/j.isci.2023.106695 　

    詳細を見る 詳細を閉じる

    Salivary gland cancers (SGCs) are heterogeneous tumors, and precision oncology represents a promising therapeutic approach; however, its impact on SGCs remains obscure. This study aimed to establish a translational model for testing molecular-targeted therapies by combining patient-derived organoids and genomic analyses of SGCs. We enrolled 29 patients, including 24 with SGCs and 5 with benign tumors. Resected tumors were subjected to organoid and monolayer cultures, as well as whole-exome sequencing. Organoid and monolayer cultures of SGCs were successfully established in 70.8% and 62.5% of cases, respectively. Organoids retained most histopathological and genetic profiles of their original tumors. In contrast, 40% of the monolayer-cultured cells did not harbor somatic mutations of their original tumors. The efficacy of molecular-targeted drugs tested on organoids depended on their oncogenic features. Organoids recapitulated the primary tumors and were useful for testing genotype-oriented molecular targeted therapy, which is valuable for precision medicine in patients with SGCs.

  39. 高用量シスプラチン併用化学放射線療法患者における高齢者総合機能評価の有用性

    宍戸 雅悠, 石井 亮, 東 賢二郎, 大越 明, 香取 幸夫

    頭頸部癌　49　(2)　130-130　2023年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  40. 頭頸部癌に対する根治的化学放射線治療における尿中NAGによる腎障害予測

    石井 亮, 東 賢二郎, 宍戸 雅悠, 大越 明, 香取 幸夫

    頭頸部癌　49　(2)　134-134　2023年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  41. 局所進行上顎洞癌に対する超選択的動注と放射線同時併用療法(JCOG1212試験) 有効性検証相(T4aN0M0)の結果

    大越 明, 四宮 弘隆, 林 隆一, 齊藤 祐毅, 別府 慎太郎, 志賀 清人, 浅田 行紀, 上村 裕和, 上田 勉, 松浦 一登, 本間 明宏

    日本耳鼻咽喉科頭頸部外科学会会報　126　(4)　630-630　2023年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  42. Eustachian Tube Functions in Concurrent Chemoradiotherapy for Head and Neck Cancer Patients. 国際誌

    Akira Ohkoshi, Ryoukichi Ikeda, Jun Suzuki, Takaya Yamamoto, Ryo Ishii, Kenjiro Higashi, Shun Wakamori, Yuki Nakayama, Ayako Nakanome, Takenori Ogawa, Yukio Katori

    Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India　74　(Suppl 3)　6307-6312　2022年12月

    DOI： 10.1007/s12070-021-03058-x 　

    詳細を見る 詳細を閉じる

    Ototoxicity is a dose-limiting adverse event for concurrent chemoradiotherapy (CCRT) with high-dose cisplatin for locally advanced head and neck squamous cell carcinoma (HNSCC). Both irradiation to the Eustachian tube (ET) and weight loss are risk factors for patulous ET. The aim of this prospective, observational study was to elucidate the incidences of patulous ET conditions before and after CCRT in HNSCC patients by means of ET function tests. This prospective, observational study was conducted in 27 HNSCC patients who received CCRT with high-dose cisplatin, and ET function tests (sonotubometry and tubo-tympano-aerodynamic graphy) were performed before and 3 months after CCRT. Factors potentially affecting the incidence of patulous ET conditions after CCRT were evaluated. Of the 54 ears from 27 patients investigated, patulous ET conditions were observed in 12 ears (22.2%) from 9 patients (33.3%) before CCRT and 15 ears (27.8%) from 11 patients (40.7%) at 3 months after CCRT. Only patulous ET conditions before CCRT in each ear were significantly associated with patulous ET conditions after CCRT (p = 0.010). This is the first report to describe the incidences of patulous ET conditions before and after CCRT in HNSCC patients. HNSCC patients are potentially at higher risk of patulous ET.

  43. 自己記入式CGAによる頭頸部がん患者の高齢に関連するアウトカムの予測

    石井 亮, 大越 明, 中山 勇樹, 東 賢二郎, 中目 亜矢子, 香取 幸夫

    日本癌治療学会学術集会抄録集　60回　P60-3　2022年10月

    出版者・発行元： (一社)日本癌治療学会

  44. 下顎正中離断・経口蓋アプローチ法と経鼻内視鏡を併用した上咽頭悪性腫瘍の切除

    佐藤 悠歩, 東 賢二郎, 石井 亮, 中山 勇樹, 中目 亜矢子, 大越 明, 香取 幸夫

    頭頸部外科　32　(2)　185-190　2022年10月

    出版者・発行元： (NPO)日本頭頸部外科学会

    ISSN：1349-581X

    eISSN：1884-474X

  45. 自己記入式CGAによる頭頸部がん患者の高齢に関連するアウトカムの予測

    石井 亮, 大越 明, 中山 勇樹, 東 賢二郎, 中目 亜矢子, 香取 幸夫

    日本癌治療学会学術集会抄録集　60回　P60-3　2022年10月

    出版者・発行元： (一社)日本癌治療学会

  46. Clinical and Epidemiological Characteristics of Bloodstream Infections in Head and Neck Cancer Patients: A Decadal Observational Study. 国際誌

    Shiori Kitaya, Risako Kakuta, Hajime Kanamori, Akira Ohkoshi, Ryo Ishii, Kazuhiro Nomura, Koichi Tokuda, Yukio Katori

    Journal of clinical medicine　11　(16)　2022年8月17日

    DOI： 10.3390/jcm11164820 　

    詳細を見る 詳細を閉じる

    This retrospective study aims to describe the clinico-epidemiological characteristics of bloodstream infections (BSIs) and the risk factors in patients with head and neck cancer (n = 227) treated at the Department of Otolaryngology, Head and Neck Surgery, Tohoku University Hospital between April 2011 and March 2021. Overall, 23.3% of blood cultures were positive. In the culture-positive group, catheter-related bloodstream infections (CRBSIs) were the most common (38.8%), followed by respiratory tract infections (19.4%), and catheter-associated urinary tract infections (6.0%). Methicillin-resistant Staphylococcus aureus (26.9%), Staphylococcus epidermidis (17.9%), and Pseudomonas aeruginosa (10.4%) infections were common. The most frequent treatment for head and neck cancer was surgery (23.9%), followed by treatment interval or palliative care (19.4%), and single radiotherapy (13.4%). The 30-day mortality rate was significantly higher in the BSI than in the non-BSI group (10.4% vs. 1.8%, respectively). CRBSIs are the most frequent source of BSIs in patients with head and neck cancer. In conclusion, central venous catheters or port insertion should be used for a short period to prevent CRBSIs. The risk of developing BSI should be considered in patients with pneumonia. Understanding the epidemiology of BSIs is crucial for diagnosing, preventing, and controlling infections in patients with head and neck cancer.

  47. Nrf2 protects against radiation-induced oral mucositis via antioxidation and keratin layer thickening. 国際誌

    Shun Wakamori, Keiko Taguchi, Yuki Nakayama, Akira Ohkoshi, Michael B Sporn, Takenori Ogawa, Yukio Katori, Masayuki Yamamoto

    Free radical biology & medicine　188　206-220　2022年6月23日

    DOI： 10.1016/j.freeradbiomed.2022.06.239 　

    詳細を見る 詳細を閉じる

    Radiation-induced oral mucositis is one of the most common adverse events in radiation therapy for head and neck cancers, but treatments for oral mucositis are limited to palliative and supportive care. New approaches are required to prevent radiation-induced mucositis and to improve treatments. The Keap1-Nrf2 system regulates cytoprotection against oxidative and electrophilic stresses. Nrf2 also regulates keratin layer thickness in mouse tongues. Therefore, we hypothesized that Nrf2 may protect the tongue epithelium against radiation-induced mucositis via elimination of reactive oxygen species and induction of keratin layer thickening. To test this hypothesis, we prepared a system for γ-ray exposure of restricted areas and irradiated the tongues of model mice with Nrf2 and Keap1 loss-of-function. We discovered that loss of Nrf2 expression indeed sensitized the tongue epithelium to radiation-induced ulcer formation with inflammation. Constitutive Nrf2 activation by genetic Keap1 knockdown alleviated radiation-induced DNA damage by increasing antioxidation. In agreement with the genetic Nrf2 activation model, the Nrf2 inducer CDDO-Im prevented irradiation damage to the tongue epithelium. These results demonstrate that Nrf2 activation has the potential to prevent the development of radiation-induced mucositis and that Nrf2 inducers are an important therapeutic drug for protection of the upper aerodigestive tract from radiation-induced mucositis.

  48. Trismus after partial maxillectomy and radiotherapy: Free flap reconstruction versus prosthetic obturation. 国際誌

    Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Ayako Nakanome, Kenichiro Ishikawa, Yukio Katori

    Auris, nasus, larynx　2022年6月7日

    DOI： 10.1016/j.anl.2022.05.016 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: Partial maxillectomy and postoperative radiotherapy are both risk factors associated with trismus. This retrospective study aimed to evaluate the incidence and severity of trismus in patients following partial maxillectomy with or without postoperative radiotherapy and to compare free flap reconstruction and prosthetic obturation. METHODS: A retrospective review of 40 oral cancer patients who underwent partial maxillectomy with or without postoperative radiotherapy was performed. Maximum interincisal distance recorded at least 6 months after surgery was classified according to a revised subjective-objective management-analytical (SOMA) scale and compared between the free flap reconstruction group (n = 12) and the prosthetic obturation group (n = 28). RESULTS: Trismus was observed in 16/40 (40%) patients, and severe trismus was observed in 4/40 (10%) patients. Although no significant difference in trismus grade was observed between the free flap reconstruction and prosthetic obturation groups, both severe trismus and radiation-induced osteonecrosis were only seen in the prosthetic obturation group with postoperative radiotherapy. CONCLUSION: Free flap reconstruction was preferable to prosthetic obturation to avoid severe trismus and radiation-induced osteonecrosis in patients who underwent both partial maxillectomy and postoperative radiotherapy.

  49. 頭頸部外来における自己記入式CGAの導入

    石井 亮, 大越 明, 東 賢二郎, 中目 亜矢子, 中山 勇樹, 香取 幸夫

    頭頸部癌　48　(2)　189-189　2022年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  50. コンピューター支援を利用した下顎再建の現状と展望 CAD/CAMを用いた下顎再建と医科歯科連携

    黒沢 是之, 大越 明, 石井 亮, 佐藤 奈央子, 宮下 仁, 今井 啓道

    頭頸部癌　48　(2)　66-66　2022年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  51. Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan. 国際誌

    Takuya Yoshida, Takenori Ogawa, Ayako Nakanome, Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Tomohiko Ishikawa, Yukio Katori, Toru Furukawa

    Auris, nasus, larynx　49　(6)　1033-1041　2022年4月28日

    DOI： 10.1016/j.anl.2022.04.006 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: This study aimed to investigate the distribution of human papillomavirus 16 (HPV16) variants that contribute to the development of HPV-related oropharyngeal carcinoma (HPV-OPC) in the Japanese population and to evaluate genetic variations in the sequence encoding the L1 antigen region of the viral outer shell that is targeted by existing vaccines and is relevant for designing a prevention strategy to combat the exponential increase in HPV-OPC cases in Japan. METHODS: Seventy Japanese HPV-OPC patients treated at Tohoku University Hospital were included in the study. DNA was extracted from formalin-fixed, paraffin-embedded tissue samples. Polymerase chain reaction and direct nucleotide sequencing were performed to determine the nucleotide polymorphisms necessary for the classification of HPV16 variants and to assess genetic diversity in the HPV16 L1 antigen region, including the BC, DE, EF, FG, and HI loops. RESULTS: The most common variant of HPV16 was the A4 sublineage (88.6%), conventionally called the Asian type, followed by the A1/2/3 (10.0%) sublineage, classified as the European type. The only nonsynonymous substitution detected in the L1 antigen loop region was p.N181T in the EF loop, which was found in 28/70 (40%) cases. In contrast, no nonsynonymous substitutions were observed in the DE, FG, and HI loops, which are particularly important regions in the antigen loop targeted by existing HPV vaccines. CONCLUSION: The most common HPV16 variant in Japanese HPV-OPC patients was the A4 subtype. The L1 antigen region is highly conserved, suggesting sufficient efficacy of existing HPV vaccines. These findings provide important information that will aid in the design of an HPV16 infection control strategy using existing HPV vaccines to prevent the spread of HPV-OPC in Japan.

  52. 頭頸部癌治療が副鼻腔粘膜に与える影響について

    鈴木 淳, 逸見 朋隆, 石井 亮, 池田 怜吉, 小林 祐太, 生島 寛享, 野村 和弘, 菅原 充, 大越 明, 香取 幸夫

    日本耳鼻咽喉科頭頸部外科学会会報　125　(4)　724-724　2022年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  53. 本邦におけるHPV関連中咽頭癌予防に向けたHPV16 Virus Variant調査とワクチン効果予測

    吉田 拓矢, 中目 亜矢子, 大越 明, 東 健次郎, 石井 亮, 石川 智彦, 古川 徹, 小川 武則, 香取 幸夫

    日本耳鼻咽喉科頭頸部外科学会会報　125　(4)　749-749　2022年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  54. 頭頸部癌治療が副鼻腔粘膜に与える影響について

    鈴木 淳, 逸見 朋隆, 石井 亮, 池田 怜吉, 小林 祐太, 生島 寛享, 野村 和弘, 菅原 充, 大越 明, 香取 幸夫

    日本耳鼻咽喉科頭頸部外科学会会報　125　(4)　724-724　2022年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：2436-5793

    eISSN：2436-5866

  55. Effect of treatments for head and neck cancer on sinus shadow on computed tomography. 国際誌

    Tomotaka Hemmi, Jun Suzuki, Ryo Ishii, Ryoukichi Ikeda, Yuta Kobayashi, Hiroyuki Ikushima, Kazuhiro Nomura, Mitsuru Sugawara, Akira Ohkoshi, Yukio Katori

    Auris, nasus, larynx　49　(6)　1019-1026　2022年3月24日

    DOI： 10.1016/j.anl.2022.03.020 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: Head and neck surgeries may cause changes in the nasal airflow, and radiotherapy irreversibly damages paranasal sinus epithelial cells. Some chemotherapeutic drugs have been reported to negatively affect airway ciliary activity in mice, and chronic rhinosinusitis could be an adverse effect of head and neck cancer (HNC) treatment. To evaluate whether HNC treatment is a risk factor for developing sinonasal mucosal thickening that may reflect paranasal sinus inflammation, we compared pre- and post-treatment paranasal sinus computed tomography (CT) images of patients treated for HNC at a single university hospital. METHODS: The patients who received curative treatment for HNC (oral, pharyngeal, and laryngeal cancers) and started receiving first-line therapy between January 2015 and December 2019 were included. Data on age, sex, primary lesion, clinical stage, treatment, smoking history, drinking history, comorbidities (diabetes and chronic lung disease), and pre- and post-treatment (three months and one year after the final treatment) paranasal sinus CT images were analyzed from medical records. Pre- and post-treatment paranasal sinus CT images were scored using the Lund-Mackay (LM) staging system. RESULTS: In total, 245 patients participated in this study. Three months after the final treatment, 80.4% of patients had no change in their total LM scores (p=0.621). Almost 80% of patients who underwent total laryngectomy also had no change in their total LM scores (p=0.833). One-third of patients with nasopharyngeal cancer (NPC) had worse LM scores after treatment (5/15), although no significant difference was observed (p=0.171). None of the various factors collected were significantly related to changes in LM scores three months after the completion of treatment. One year after the final treatment, 211 patients were included and no significant changes in the pre-and post-LM scores were observed in the same analyses, while changes in LM scores were significantly different between T categories (T1-2 vs. T3-4) (p=0.020). CONCLUSION: We found no significant changes in the LM scores after HNC treatment in all the patients, which implies that HNC treatment may not be an apparent risk factor for sinonasal mucosal inflammation.

  56. Management of elderly patients with head and neck cancer. 国際誌

    Ryo Ishii, Akira Ohkoshi, Naomi Kiyota, Kazuto Matsuura, Koichi Yasuda, Yoshinori Imamura, Yuki Saito, Akihiro Homma

    Japanese journal of clinical oncology　2022年2月15日

    DOI： 10.1093/jjco/hyac013 　

    詳細を見る 詳細を閉じる

    There are no established guidelines for managing older patients with head and neck cancer. Most clinical trials that define current standard therapy included few elderly patients. On the other hand, there is great variability in patients' comorbidities, physical functions, cognitive function, familial and financial background and values. The key point appears to be appropriate geriatric assessment, clarifying the patients' outcomes and a multidisciplinary team approach, including the treatment decision-making policy. Although these processes should be scientific in nature, the evidence for the treatment of elderly head and neck patients is very limited. This review summarizes the evidence available regarding the management of geriatric assessment, each treatment modality and the multidisciplinary team approach for older patients with head and neck cancers.

  57. High diagnostic accuracy for lymph node metastasis of oral squamous cell carcinoma using PET/CT with a silicon photomultiplier.

    Ikuho Kojima, Kentaro Takanami, Takenori Ogawa, Kenichiro Ishikawa, Yohei Morishita, Ryo Ishii, Akira Ohkoshi, Ayako Nakanome, Hayato Odagiri, Masahiro Iikubo

    Oral radiology　38　(4)　540-549　2022年1月21日

    DOI： 10.1007/s11282-022-00588-0 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: The higher sensitivity of the new-generation positron emission tomography/computed tomography (PET/CT) with silicon photomultiplier (SiPM) may increase false-positive rates in detecting metastatic lymph nodes (LNs). This study aimed to clarify the usefulness of the SiPM PET scanner in diagnosing LN metastasis of oral squamous cell carcinoma (SCC). METHODS: We retrospectively reviewed consecutive F-18 fluorodeoxyglucose PET/CT images of 39 SCC patients using SiPM PET and 31 SCC patients using non-SiPM PET. We measured the maximum standardized uptake value (SUVmax) of the LNs on PET images and maximum short-axis diameter on transverse CT images. RESULTS: The sensitivity and specificity of SiPM PET were 86.2% and 95.6%, respectively (cut-off SUVmax, 4.6). The area under the curve (AUC) of SiPM PET (0.977; 95% confidence interval [CI], 0.958-0.995) was significantly higher than that of non-SiPM PET (0.825; 95% CI 0.717-0.934) (P < 0.01). In a size-limited analysis of diameter, the AUC of SiPM PET (≥ 0.96 for all diameters) was significantly higher than that of non-SiPM PET (tended to decrease as the LN diameter decreased) for the diagnosis of LN metastasis by SUVmax. CONCLUSION: SiPM PET had higher diagnostic accuracy for LN metastasis of oral SCC than non-SiPM PET, even for small LN metastasis without increasing false-positives.

  58. 頭頸部癌に対する個別化治療の試み 高齢者頭頸部癌に対する個別化医療

    小川 武則, 大越 明, 石井 亮, 中目 亜矢子

    日本癌治療学会学術集会抄録集　59回　SY9-3　2021年10月

    出版者・発行元： (一社)日本癌治療学会

  59. 高齢者機能評価スクリーニングを用いた頭頸部癌化学療法の有害事象予測

    石井 亮, 中目 亜矢子, 高橋 昌宏, 大越 明, 香取 幸夫

    日本癌治療学会学術集会抄録集　59回　O40-4　2021年10月

    出版者・発行元： (一社)日本癌治療学会

  60. Impact of CAD/CAM mandibular reconstruction on chewing and swallowing function after surgery for locally advanced oral cancer: A retrospective study of 50 cases

    Akira Ohkoshi, Naoko Sato, Koreyuki Kurosawa, Hitoshi Miyashita, Ryo Ishii, Ayako Nakanome, Takenori Ogawa, Masahiro Tachi, Tetsu Takahashi, Yukio Katori

    Auris Nasus Larynx　48　(5)　1007-1012　2021年10月

    DOI： 10.1016/j.anl.2021.03.014 　

    ISSN：0385-8146

    eISSN：1879-1476

  61. Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study

    Akira Ohkoshi, Ryo Ishii, Shun Wakamori, Yuki Nakayama, Takuya Yoshida, Kenjiro Higashi, Ayako Nakanome, Takenori Ogawa, Yukio Katori

    Oral Oncology　121　2021年10月

    DOI： 10.1016/j.oraloncology.2021.105475 　

    ISSN：1368-8375

    eISSN：1879-0593

  62. Changes in tongue pressure and dysphagia at oral cancer patients by palatal augmentation prosthesis. 国際誌

    Izumita Kuniyuki, Takuma Hisaoka, Ryoukichi Ikeda, Jun Suzuki, Naoko Sato, Ryo Tagaino, Tomonori Kambayashi, Ai Hirano-Kawamoto, Jun Ohta, Akira Ohkoshi, Ryo Ishii, Naru Shitraishi, Kengo Kato, Shigeto Koyama, Keiichi Sasaki, Yukio Katori

    Cancer reports (Hoboken, N.J.)　5　(7)　e1516　2021年9月2日

    DOI： 10.1002/cnr2.1516 　

    詳細を見る 詳細を閉じる

    BACKGROUND: The palatal augmentation prosthesis (PAP) is an intraoral prosthesis used in the treatment of dysphagia. AIM: The objective of the study is to examine the effect of PAP using tongue pressure and the Videofluoroscopic Dysphagia Scale (VDS) to understand the precise mechanism for improvement in swallowing function with PAP for oral cancer at retrospective survey. METHODS AND RESULTS: Fifteen patients were provided PAPs. Tongue pressure and VDS were evaluated with and without PAP. After intervention with PAP, tongue pressure significantly increased as compared to when without PAP (p < .05). The total mean VDS score with PAP was found to have significantly improved (p < .05). The mean VDS score of the oral phase also significantly improved with the PAP compared to without the PAP group (p < .05). Significant differences (p < .01) were found in each category, such as tongue to palate contact and pyriform sinus residue. CONCLUSION: PAP can improve tongue pressure, tongue to palate contact, and pyriform sinus residue.

  63. 喉頭に発生した炎症性筋線維芽細胞性腫瘍による上気道閉塞に対して緊急気管切開術を施行した1例

    芦澤 翔平, 舘田 勝, 菊地 俊晶, 石田 英一, 櫻田 潤子, 鈴木 博義, 小笠原 真理, 長谷川 航世, 池田 怜吉, 大越 明

    仙台医療センター医学雑誌　11　(2)　41-45　2021年6月

    出版者・発行元： (独)国立病院機構仙台医療センター

    ISSN：2186-0920

    eISSN：2186-3946

  64. リンパ節サイズに着目した半導体および非半導体PET装置の口腔扁平上皮癌リンパ節転移の診断精度

    小嶋 郁穂, 高浪 健太郎, 小川 武則, 石川 健一朗, 森下 陽平, 石井 亮, 大越 明, 中目 亜矢子, 飯久保 正弘

    歯科放射線　61　(増刊)　44-44　2021年5月

    出版者・発行元： (NPO)日本歯科放射線学会

    ISSN：0389-9705

    eISSN：2185-6311

  65. 頭頸部癌治療に関わる嚥下障害および肺炎の発生についての後方視的研究

    石井 亮, 中山 勇樹, 中村 和樹, 吉田 拓矢, 石川 智彦, 若盛 隼, 六郷 正博, 中目 亜矢子, 西條 聡, 今井 隆之, 山崎 知子, 大越 明, 浅田 行紀, 香取 幸夫

    頭頸部癌　47　(2)　220-220　2021年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  66. 唾液腺導管癌の患者由来オルガノイド細胞株を用いた個別化医療モデル

    石川 智彦, 中目 亜矢子, 大越 明, 東 賢二郎, 石井 亮, 六郷 正博, 若盛 隼, 吉田 拓矢, 小川 武則, 古川 徹, 香取 幸夫

    日本耳鼻咽喉科学会会報　124　(4)　591-591　2021年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：0030-6622

    eISSN：1883-0854

  67. 唾液腺導管癌の患者由来オルガノイド細胞株を用いた個別化医療モデル

    石川 智彦, 中目 亜矢子, 大越 明, 東 賢二郎, 石井 亮, 六郷 正博, 若盛 隼, 吉田 拓矢, 小川 武則, 古川 徹, 香取 幸夫

    日本耳鼻咽喉科学会会報　124　(4)　591-591　2021年4月

    出版者・発行元： (一社)日本耳鼻咽喉科頭頸部外科学会

    ISSN：0030-6622

    eISSN：1883-0854

  68. 外来診療における私の処置 咽喉頭の処置 永久気管孔の処置

    大越 明, 香取 幸夫

    JOHNS　37　(2)　203-205　2021年2月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  69. Simultaneous evaluation of symptoms, swallowing functions, and patient-reported swallowing difficulties and their correlations with ingestion status during definitive chemoradiotherapy for oropharyngeal and hypopharyngeal cancer

    Ryo Ishii, Kengo Kato, Akira Ohkoshi, Takeshi Sato, Ai Hirano, Takenori Ogawa, Yukio Katori

    Supportive Care in Cancer　29　(2)　955-964　2021年2月

    DOI： 10.1007/s00520-020-05570-2 　

    ISSN：0941-4355

    eISSN：1433-7339

  70. Simple Endoscopic Method of Scoring Swallowing Function After Treatment in Advanced Head and Neck Cancer Patients

    Akira Ohkoshi, Takenori Ogawa, Kengo Kato, Ayako Nakanome, Ryo Ishii, Takuya Yoshida, Yuki Nakayama, Yukio Katori

    Indian Journal of Otolaryngology and Head and Neck Surgery　2021年

    DOI： 10.1007/s12070-020-02307-9 　

    ISSN：2231-3796

    eISSN：0973-7707

  71. Use of the geriatric-8 screening tool to predict prognosis and complications in older adults with head and neck cancer: A prospective, observational study

    Ryo Ishii, Takenori Ogawa, Akira Ohkoshi, Ayako Nakanome, Masahiro Takahashi, Yukio Katori

    Journal of Geriatric Oncology　2021年

    DOI： 10.1016/j.jgo.2021.03.008 　

    ISSN：1879-4068

  72. The geriatric-8 screening tool for predicting complications in older adults after surgery for locally advanced head and neck cancer with free flap reconstruction

    Yuki Nakayama, Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Ayako Nakanome, Takenori Ogawa, Yukio Katori

    European Archives of Oto-Rhino-Laryngology　2021年

    DOI： 10.1007/s00405-021-07038-3 　

    ISSN：0937-4477

    eISSN：1434-4726

  73. 3Dモデルと配列用トレーを用いた遊離腓骨皮弁による下顎再建へのアプローチ

    宮下 仁, 佐藤 奈央子, 北村 淳, 原田 貴之, 加藤 裕光, 高木 尚之, 黒沢 是之, 小川 武則, 大越 明, 小山 重人, 佐々木 啓一, 高橋 哲

    顎顔面補綴　43　(2)　48-53　2020年12月

    出版者・発行元： (一社)日本顎顔面補綴学会

    ISSN：0389-4045

  74. 3Dモデルと配列用トレーを用いた遊離腓骨皮弁による下顎再建へのアプローチ

    宮下 仁, 佐藤 奈央子, 北村 淳, 原田 貴之, 加藤 裕光, 高木 尚之, 黒沢 是之, 小川 武則, 大越 明, 小山 重人, 佐々木 啓一, 高橋 哲

    顎顔面補綴　43　(2)　48-53　2020年12月

    出版者・発行元： (一社)日本顎顔面補綴学会

    ISSN：0389-4045

    eISSN：2435-0389

  75. Improvement of a delayed swallowing reflex following treatment for advanced head and neck cancer 国際誌

    Akira Ohkoshi, Kengo Kato, Takenori Ogawa, Ayako Nakanome, Ryo Ishii, Yukio Katori

    Cancers of the Head & Neck　5　(1)　8-8　2020年12月

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1186/s41199-020-00055-5 　

    eISSN：2059-7347

    詳細を見る 詳細を閉じる

    <title>Abstract</title><sec> <title>Background</title> The latency of the swallowing reflex is an important factor causing dysphagia in head and neck cancer patients. Although there are many reports comparing voluntary swallowing function before and after treatment, few studies have focused on the latency of the swallowing reflex, which is a risk factor for pneumonia due to silent aspiration. The aim of this retrospective study was to clarify the changes in the latency of the swallowing reflex before and after treatment. </sec><sec> <title>Methods</title> The latency of the swallowing reflex was quantified using the time from the injection of 1 ml of distilled water into the pharynx through a nasal catheter to the onset of swallowing. </sec><sec> <title>Results</title> The latency time of the swallowing reflex was significantly decreased 3 months after treatment compared to before treatment. A significant reduction was also observed in patients with pharyngeal cancer who underwent chemoradiation therapy. </sec><sec> <title>Conclusions</title> This retrospective study showed that a delayed swallowing reflex improved with treatment in advanced head and neck cancer patients. </sec><sec> <title>Trial registration</title> The Institutional Review Board of Tohoku University Hospital (Number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.rinri.med.tohoku.ac.jp/esct">2014–1-274</ext-link>). </sec>

  76. Parotid secretory carcinoma with high-grade transformation

    Yuki Numano, Takenori Ogawa, Tomohiko Ishikawa, Hajime Usubuchi, Ayako Nakanome, Akira Ohkoshi, Eiichi Ishida, Masahiro Rokugo, Yukio Katori

    Auris Nasus Larynx　47　(6)　1043-1048　2020年12月

    DOI： 10.1016/j.anl.2019.10.003 　

    ISSN：0385-8146

    eISSN：1879-1476

  77. Clinical utility of apparent diffusion coefficient and diffusion-weighted magnetic resonance imaging for resectability assessment of head and neck tumors with skull base invasion

    Takenori Ogawa, Ikuho Kojima, Shun Wakamori, Takuya Yoshida, Takaki Murata, Maya Sakamoto, Akira Ohkoshi, Ayako Nakanome, Hidenori Endo, Toshiki Endo, Hajime Usubuchi, Yukio Katori

    Head and Neck　42　(10)　2896-2904　2020年10月1日

    DOI： 10.1002/hed.26336 　

    ISSN：1043-3074

    eISSN：1097-0347

  78. 【耳鼻咽喉科診療Q&A】頸部領域、頭頸部腫瘍 下顎切除後の機能温存の治療をどのようにしていますか?

    大越 明, 黒沢 是之, 宮下 仁, 佐藤 奈央子, 中目 亜矢子, 小川 武則, 香取 幸夫

    JOHNS　36　(9)　1283-1285　2020年9月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  79. 頭頸部癌化学放射線治療前後の嚥下評価方法の検証 嚥下内視鏡・造影検査の経時比較

    石井 亮, 加藤 健吾, 大越 明, 佐藤 剛史, 平野 愛, 小川 武則, 香取 幸夫

    口腔・咽頭科　33　(3)　175-175　2020年8月

    出版者・発行元： 日本口腔・咽頭科学会

    ISSN：0917-5105

    eISSN：1884-4316

  80. Management of adenoid cystic carcinoma of the head and neck: A single-institute study with over 25-year follow-up

    Eiichi Ishida, Takenori Ogawa, Masahiro Rokugo, Tomohiko Ishikawa, Shun Wakamori, Akira Ohkoshi, Hajime Usubuchi, Kenjiro Higashi, Ryo Ishii, Ayako Nakanome, Yukio Katori

    Head and Face Medicine　16　(1)　2020年7月2日

    DOI： 10.1186/s13005-020-00226-2 　

    eISSN：1746-160X

  81. 3Dモデルと装着型配列ガイドを用いた遊離腓骨皮弁による下顎再建へのシンプルアプローチ

    宮下 仁, 佐藤 奈央子, 北村 淳, 原田 貴之, 泉田 賢一, 高木 尚之, 黒沢 是之, 小川 武則, 大越 明, 加藤 裕光, 小山 重人, 佐々木 啓一, 高橋 哲

    頭頸部癌　46　(2)　211-211　2020年7月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  82. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck

    Tomohiro Enokida, Takenori Ogawa, Akihiro Homma, Kenji Okami, Shujiro Minami, Ayako Nakanome, Yasushi Shimizu, Daisuke Maki, Yuri Ueda, Takao Fujisawa, Atsushi Motegi, Akira Ohkoshi, Jun Taguchi, Koji Ebisumoto, Shogo Nomura, Susumu Okano, Makoto Tahara

    Cancer Medicine　9　(5)　1671-1682　2020年3月1日

    DOI： 10.1002/cam4.2852 　

    eISSN：2045-7634

  83. 【カラーアトラス 口腔・咽頭粘膜疾患-目で見て覚える鑑別ポイント】咽頭粘膜の悪性腫瘍

    中山 勇樹, 小川 武則, 大越 明, 中目 亜矢子, 吉田 拓矢, 小泉 祥太郎, 香取 幸夫

    耳鼻咽喉科・頭頸部外科　92　(2)　152-160　2020年2月

    出版者・発行元： (株)医学書院

    ISSN：0914-3491

    eISSN：1882-1316

  84. Malignant surface epithelial tumours of the pharynx

    Yuki Nakayama, Takenori Ogawa, Akira Ohkoshi

    Otolaryngology - Head and Neck Surgery (Japan)　92　(2)　152-160　2020年

    ISSN：0914-3491

  85. 【私はこうしている-口腔咽喉頭頸部手術編】口腔・咽頭手術 下顎悪性腫瘍切除術 下顎骨区域切除

    小川 武則, 黒沢 是之, 宮下 仁, 佐藤 奈央子, 大越 明, 中目 亜矢子, 吉田 拓矢, 石川 健一朗, 遠藤 拓弥, 香取 幸夫

    JOHNS　35　(9)　1093-1096　2019年9月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  86. 【私はこうしている-口腔咽喉頭頸部手術編】頸部・甲状腺・食道手術 術後瘻孔閉鎖術

    大越 明, 黒沢 是之, 小川 武則, 中目 亜矢子, 吉田 拓矢, 香取 幸夫

    JOHNS　35　(9)　1339-1342　2019年9月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  87. Successful Multidisciplinary Treatment Accomplished by Collaboration of Multiple Clinical Departments for Synchronous Quadruple Cancer

    Shunsuke Eba, Hirotsugu Notsuda, Fumihiko Hoshi, Hisashi Oishi, Yasushi Matsuda, Tetsu Sado, Masafumi Noda, Akira Sakurada, Ken Saijo, Akira Okoshi, Naoki Tanaka, Yoshinori Okada

    Kyobu geka. The Japanese journal of thoracic surgery　72　(9)　655-657　2019年9月1日

    ISSN：0021-5252

  88. 東北大学における下咽頭癌200例の臨床統計

    中目 亜矢子, 小川 武則, 嵯峨井 俊, 大越 明, 東 賢二郎, 石井 亮, 香取 幸夫

    耳鼻咽喉科展望　62　(補冊1)　22-23　2019年6月

    出版者・発行元： 耳鼻咽喉科展望会

    ISSN：0386-9687

    eISSN：1883-6429

  89. 東北大学における舌癌を除く口腔癌179例の臨床統計

    小川 武則, 中目 亜矢子, 石井 亮, 嵯峨井 俊, 大越 明, 東 賢二郎, 加藤 健吾, 香取 幸夫

    耳鼻咽喉科展望　62　(補冊1)　48-49　2019年6月

    出版者・発行元： 耳鼻咽喉科展望会

    ISSN：0386-9687

    eISSN：1883-6429

  90. 頭頸部癌診療における高齢者機能評価スクリーニングツールG8の役割

    石井 亮, 小川 武則, 大越 明, 中目 亜矢子, 六郷 正博, 香取 幸夫

    頭頸部癌　45　(2)　128-128　2019年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  91. 頭蓋底浸潤頭頸部悪性腫瘍のMRI像

    小川 武則, 中目 亜矢子, 大越 明, 六郷 正博, 若盛 隼, 吉田 拓矢, 臼渕 肇, 香取 幸夫

    日本耳鼻咽喉科学会会報　122　(4)　632-632　2019年4月

    出版者・発行元： (一社)日本耳鼻咽喉科学会

    ISSN：0030-6622

    eISSN：1883-0854

  92. Intestinal type adenocarcinoma of nasal cavity―a case report and literature review―

    Kazuki Nakamura, Takenori Ogawa, Ayako Nakanome, Akira Ohkoshi, Eiichi Ishida, Masahiro Rokugo, Tomohiko Ishikawa, Shun Wakamori, Takuya Yoshida, Yukio Katori

    Japanese Journal of Head and Neck Cancer　45　(3)　337-341　2019年

    DOI： 10.5981/jjhnc.45.337 　

    ISSN：1349-5747

    eISSN：1881-8382

  93. 【頸部腫瘤を熟知する】頸部腫瘤の診断手順 頸部腫瘤を診る 細胞診、組織診 CTガイド下のcore needle biopsy

    小川 武則, 常陸 真, 石井 亮, 石川 智彦, 六郷 正博, 中目 亜矢子, 石田 英一, 大越 明, 香取 幸夫

    JOHNS　34　(12)　1678-1682　2018年12月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  94. Predictors of chewing and swallowing disorders after surgery for locally advanced oral cancer with free flap reconstruction: A prospective, observational study

    Akira Ohkoshi, Takenori Ogawa, Ayako Nakanome, Eiichi Ishida, Ryo Ishii, Kengo Kato, Yukio Katori

    Surgical Oncology　27　(3)　490-494　2018年9月

    DOI： 10.1016/j.suronc.2018.05.029 　

    ISSN：0960-7404

    eISSN：1879-3320

  95. 嚥下障害への対応Up to Date 頭頸部癌治療にともなう嚥下障害への治療戦略

    石井 亮, 加藤 健吾, 平野 愛, 佐藤 剛史, 大越 明, 小川 武則, 松浦 一登, 香取 幸夫

    口腔・咽頭科　31　(3)　238-238　2018年8月

    出版者・発行元： 日本口腔・咽頭科学会

    ISSN：0917-5105

    eISSN：1884-4316

  96. 頭頸部がん治療後における嚥下内視鏡検査の有用性

    大越 明, 石井 亮, 加藤 健吾, 香取 幸夫

    口腔・咽頭科　31　(3)　327-327　2018年8月

    出版者・発行元： 日本口腔・咽頭科学会

    ISSN：0917-5105

    eISSN：1884-4316

  97. 頭頸部癌における高齢者機能評価スクリーニングツールの有用性

    石井 亮, 小川 武則, 高橋 昌宏, 嵯峨井 俊, 中目 亜矢子, 大越 明, 東 賢二郎, 白倉 真之, 香取 幸夫

    頭頸部外科　28　(1)　55-61　2018年6月

    出版者・発行元： (NPO)日本頭頸部外科学会

    ISSN：1349-581X

    eISSN：1884-474X

  98. Poor oral intake causes enteral nutrition dependency after concomitant chemoradiotherapy for pharyngeal cancers

    Ryo Ishii, Kengo Kato, Takenori Ogawa, Takeshi Sato, Ayako Nakanome, Akira Ohkoshi, Ai Kawamoto-Hirano, Masayuki Shirakura, Hiroshi Hidaka, Yukio Katori

    European Archives of Oto-Rhino-Laryngology　275　(6)　1607-1611　2018年6月1日

    DOI： 10.1007/s00405-018-4963-y 　

    ISSN：0937-4477

    eISSN：1434-4726

  99. Clinical utility of dynamic-enhanced MRI in salivary gland tumors: retrospective study and literature review

    Takenori Ogawa, Ikuho Kojima, Ryo Ishii, Maya Sakamoto, Takaki Murata, Takahiro Suzuki, Kengo Kato, Ayako Nakanome, Akira Ohkoshi, Eiichi Ishida, Seiji Kakehata, Kiyoto Shiga, Yukio Katori

    European Archives of Oto-Rhino-Laryngology　275　(6)　1613-1621　2018年6月1日

    DOI： 10.1007/s00405-018-4965-9 　

    ISSN：0937-4477

    eISSN：1434-4726

  100. 【手術に必要な画像診断-口腔・咽頭編】下歯肉・下顎腫瘍切除術

    石田 英一, 小川 武則, 小嶋 郁穂, 大越 明, 石井 亮, 川村 善宜, 石川 智彦, 橋本 光, 香取 幸夫

    JOHNS　34　(5)　583-587　2018年5月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  101. 下歯肉癌手術における下顎骨切除範囲と術後機能の検討

    小川 武則, 大越 明, 石田 英一, 石井 亮, 石川 智彦, 宮下 仁, 永井 宏和, 佐藤 奈央子, 小山 重人, 高地 崇, 高木 尚之, 香取 幸夫

    頭頸部癌　44　(2)　168-168　2018年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  102. 舌癌を除く口腔癌179例の臨床統計

    六郷 正博, 小川 武則, 中目 亜矢子, 大越 明, 石田 英一, 石井 亮, 石川 智彦, 香取 幸夫

    頭頸部癌　44　(2)　140-140　2018年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  103. 頭頸部腺様嚢胞癌63例の臨床統計

    石田 英一, 石井 亮, 六郷 正博, 東 賢二郎, 石川 智彦, 佐藤 亜矢子, 大越 明, 小川 武則, 香取 幸夫

    日本耳鼻咽喉科学会会報　121　(4)　542-542　2018年4月

    出版者・発行元： (一社)日本耳鼻咽喉科学会

    ISSN：0030-6622

    eISSN：1883-0854

  104. 高齢者機能評価スクリーニングツールG8の治療選択に対する有用性

    石井 亮, 大越 明, 石田 英一, 石川 智彦, 川村 善宣, 小川 武則, 香取 幸夫

    日本耳鼻咽喉科学会会報　121　(4)　589-589　2018年4月

    出版者・発行元： (一社)日本耳鼻咽喉科学会

    ISSN：0030-6622

    eISSN：1883-0854

  105. 局所進行口腔癌手術における摂食嚥下障害の危険因子の検討

    大越 明, 石田 英一, 小川 武則, 中目 亜矢子, 石井 亮, 加藤 健吾, 香取 幸夫

    日本耳鼻咽喉科学会会報　121　(4)　552-552　2018年4月

    出版者・発行元： (一社)日本耳鼻咽喉科学会

    ISSN：0030-6622

    eISSN：1883-0854

  106. Simple laryngeal suspension procedure by suturing the digastric muscle to the periosteum of the mandible in neck dissection for tongue cancer

    Akira Ohkoshi, Takenori Ogawa, Shun Sagai, Ayako Nakanome, Kenjiro Higashi, Ryo Ishii, Kengo Kato, Yukio Katori

    American Journal of Otolaryngology - Head and Neck Medicine and Surgery　39　(2)　77-81　2018年3月

    DOI： 10.1016/j.amjoto.2018.01.008 　

    ISSN：0196-0709

    eISSN：1532-818X

  107. 頭頸部原発骨肉腫の6例

    嵯峨井 俊, 小川 武則, 臼渕 肇, 小嶋 郁穂, 村田 隆紀, 阪本 真弥, 高橋 昌宏, 西條 憲, 加藤 健吾, 中目 亜矢子, 大越 明, 東 賢二郎, 石井 亮, 香取 幸夫

    頭頸部外科　27　(3)　379-385　2018年2月

    出版者・発行元： (NPO)日本頭頸部外科学会

    ISSN：1349-581X

    eISSN：1884-474X

  108. 【こんなときどうする? 術中・術後のトラブル対応】《咽喉頭・頭頸部領域》 乳糜漏が止まらない

    小川 武則, 大越 明, 香取 幸夫

    耳鼻咽喉科・頭頸部外科　90　(1)　66-69　2018年1月

    出版者・発行元： (株)医学書院

    ISSN：0914-3491

    eISSN：1882-1316

  109. 症例をどうみるか MRIが診断に有用であった頭頸部悪性腫瘍の2症例

    中目 亜矢子, 小川 武則, 小嶋 郁穂, 阪本 真弥, 村田 隆紀, 臼渕 肇, 石井 亮, 川村 善宜, 大越 明, 嵯峨井 俊, 香取 幸夫

    JOHNS　34　(1)　132-137　2018年1月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

    詳細を見る 詳細を閉じる

    DWI、ADC値を用いたMRI診断が有用であった化学療法、放射線治療後頭頸部悪性腫瘍の2症例(症例1:28歳男性、症例2:65歳男性)について報告した。今回の2症例では、化学療法による腫瘍細胞密度の低下(細胞間質の増加)や(症例1)、手術後の非再発性変化(症例2)をDWI低信号、ADC高値として描出しており、DWI、ADC画像を用いたMRI撮影は、頭頸部悪性腫瘍治療後FDG-PET陽性例に対する追加検査として有用であると考えられた。

  110. Continuation of chylorrhea

    Takenori Ogwa, Akira Okoshi, Yukio Katori

    Otolaryngology - Head and Neck Surgery (Japan)　90　(1)　66-69　2018年1月

    ISSN：0914-3491

  111. 頭蓋底浸潤鼻副鼻腔悪性腫瘍に対する治療戦略

    小川 武則, 小嶋 郁穂, 村田 隆紀, 阪本 真弥, 岸田 佳太, 高橋 紀善, 松下 晴雄, 荒川 一弥, 野村 和弘, 中目 亜矢子, 大越 明, 東 賢二郎, 石井 亮, 嵯峨井 俊, 神宮 啓一, 香取 幸夫

    頭頸部癌　43　(4)　409-414　2017年12月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  112. 【頭頸部悪性腫瘍の疑問に答える】治療後の対応 放射線治療後の唾液分泌障害や高度嚥下障害に対する対応を教えてください

    小川 武則, 石井 亮, 大越 明, 加藤 健吾, 嵯峨井 俊, 中目 亜矢子, 岩崎 さや香, 細川 亮一, 香取 幸夫

    JOHNS　33　(9)　1346-1350　2017年9月

    出版者・発行元： (株)東京医学社

    ISSN：0910-6820

  113. 東北大学における若年者舌癌の治療の検討

    石井 亮, 小川 武則, 白倉 真之, 東 賢二郎, 大越 明, 嵯峨井 俊, 香取 幸夫

    耳鼻咽喉科展望　60　(補冊1)　42-43　2017年6月

    出版者・発行元： 耳鼻咽喉科展望会

    ISSN：0386-9687

    eISSN：1883-6429

  114. 耳下腺および副咽頭間隙腫瘍をはじめとする頭頸部腫瘍に対するcore needle biopsyの有用性

    石井 亮, 小川 武則, 臼渕 肇, 白倉 真之, 東 賢二郎, 中目 亜矢子, 大越 明, 嵯峨井 俊, 香取 幸夫

    頭頸部癌　43　(2)　188-188　2017年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  115. 当科における下咽頭食道重複癌の検討

    東 賢二郎, 小川 武則, 嵯峨井 俊, 中目 亜矢子, 大越 明, 石井 亮, 香取 幸夫

    頭頸部癌　43　(2)　274-274　2017年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  116. MRIで悪性腫瘍箇所を同定し得た耳下腺多形腺腫由来癌の1例

    若盛 隼, 小川 武則, 臼渕 肇, 阪本 真弥, 小嶋 郁穂, 村田 隆紀, 嵯峨井 俊, 中目 亜矢子, 大越 明, 東 賢二郎, 石井 亮, 白倉 真之, 石川 智彦, 香取 幸夫

    頭頸部外科　26　(3)　389-393　2017年2月

    出版者・発行元： (NPO)日本頭頸部外科学会

    ISSN：1349-581X

    eISSN：1884-474X

  117. 【頭頸部癌学-診断と治療の最新研究動向-】頭頸部癌の疫学 我が国における頭頸部癌の疫学的動向

    小川 武則, 嵯峨井 俊, 中目 亜矢子, 大越 明, 香取 幸夫

    日本臨床　75　(増刊2 頭頸部癌学)　47-52　2017年2月

    出版者・発行元： (株)日本臨床社

    ISSN：0047-1852

  118. Treatment strategy for sinonasal malignant tumor with skull base invasion

    Takenori Ogawa, Ikuho Kojima, Takaki Murata, Maya Sakamoto, Keita Kishida, Noriyoshi Takahashi, Haruo Matsushita, Kazuya Arakawa, Kazuhiro Nomura, Ayako Nakanome, Akira Okoshi, Kenjiro Higashi, Ryo Ishii, Shun Sagai, Keiichi Jingu, Yukio Katori

    Japanese Journal of Head and Neck Cancer　43　(4)　409-414　2017年

    DOI： 10.5981/jjhnc.43.409 　

    ISSN：1349-5747

    eISSN：1881-8382

  119. 嗅神経芽細胞腫の臨床検討

    白倉 真之, 小川 武則, 中目 亜矢子, 大越 明, 香取 幸夫

    耳鼻咽喉科臨床 補冊　(補冊146)　70-70　2016年6月

    出版者・発行元： 耳鼻咽喉科臨床学会

    ISSN：0912-1870

    eISSN：2185-1557

  120. 咽頭癌化学放射線療法における絶食期間および胃瘻離脱困難の検討

    石井 亮, 白倉 真之, 平野 愛, 鹿島 和孝, 東 賢二郎, 大越 明, 中目 亜矢子, 嵯峨井 俊, 加藤 健吾, 小川 武則, 香取 幸夫

    頭頸部癌　42　(2)　183-183　2016年5月

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN：1349-5747

    eISSN：1881-8382

  121. 下咽頭・食道重複癌に対する治療強度と忍容性

    石井 亮, 小川 武則, 嵯峨井 俊, 大越 明, 東 賢二郎, 香取 幸夫

    日本気管食道科学会会報　67　(2)　s22-s22　2016年4月

    出版者・発行元： (NPO)日本気管食道科学会

    ISSN：0029-0645

    eISSN：1880-6848

  122. Transcanal endoscopic resection for leiomyoma of the external auditory canal and a review of the literature

    Ryoukichi Ikeda, Masaru Tateda, Akira Okoshi, Shinkichi Morita, Hiroyoshi Suzuki, Sho Hashimoto

    Auris Nasus Larynx　43　(1)　97-99　2016年2月1日

    DOI： 10.1016/j.anl.2015.05.003 　

    ISSN：0385-8146

    eISSN：1879-1476

  123. 経外耳道的に摘出し得た外耳道平滑筋腫の1例

    池田 怜吉, 舘田 勝, 大越 明, 森田 真吉, 鈴木 博義, 橋本 省

    日本耳鼻咽喉科学会会報　119　(6)　908-908　2016年

    出版者・発行元： 一般社団法人 日本耳鼻咽喉科学会

    DOI： 10.3950/jibiinkoka.119.908 　

  124. Extraosseous chondroma of anterior neck in pediatric patient

    Ryoukichi Ikeda, Masaru Tateda, Akira Okoshi, Shinkichi Morita, Sho Hashimoto

    International Journal of Pediatric Otorhinolaryngology　79　(8)　1374-1376　2015年

    DOI： 10.1016/j.ijporl.2015.06.011 　

    ISSN：0165-5876

    eISSN：1872-8464

  125. Roles of keap1-Nrf2 system in upper aerodigestive tract carcinogenesis

    Akira Ohkoshi, Takafumi Suzuki, Masao Ono, Toshimitsu Kobayashi, Masayuki Yamamoto

    Cancer Prevention Research　6　(2)　149-159　2013年2月

    DOI： 10.1158/1940-6207.CAPR-12-0401-T 　

    ISSN：1940-6207

    eISSN：1940-6215

  126. Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma

    Akira Okoshi, Kiyoto Shiga, Kazuha Sasaki, Yukinori Asada, Hitosni Nishikawa, Toshimitsu Kobayashi, Mika Watanabe

    Journal of Otolaryngology of Japan　111　(7)　533-536　2008年7月

    DOI： 10.3950/jibiinkoka.111.533 　

    ISSN：0030-6622

  127. Defucosylated Anti-CD44 Monoclonal Antibodies Exert Antitumor Activities against Esophageal Tumor Xenograft

    Akira Ohkoshi

    DOI： 10.20944/preprints202403.1500.v1 　

︎全件表示 ︎最初の5件までを表示

MISC 16

  1. 超音波振動を利用した口腔粘膜からの細胞採取デバイス

    小島蒼生, 芳賀洋一, 芳賀洋一, 鶴岡典子, 葉煬, 久岡巧麻, 大越明, 香取幸夫

    日本生体医工学会大会プログラム・抄録集(Web)　63rd　2024年

  2. Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy

    Susumu Okano, Makoto Tahara, Yoshinori Imamura, Hideoki Uryu, Tomoyuki Otsuka, Akira Ohkoshi, Daisuke Sano, Kiyoaki Tsukahara, Kazuchika Ono, Toyoyuki Hanazawa, Satoshi Kano, Naoki Nishio, Masato Nagaoka, Naomi Kiyota

    JOURNAL OF CLINICAL ONCOLOGY　41　(16)　2023年6月1日

    ISSN： 0732-183X

    eISSN： 1527-7755

  3. 3D-VR画像による評価と経鼻中隔アプローチによる鼻内視鏡下摘出術が有用であった上咽頭異物の1例

    中山勇樹, 鈴木淳, 太田淳, 平野愛, 高橋ひより, 中角美穂, 大越明, 香取幸夫

    日本耳鼻咽喉科頭頚部外科学会会報　125　(4)　2022年

    ISSN： 2436-5793

  4. Characteristics of aspiration pneumonia patients in acute care hospitals: A multicenter, retrospective survey in Northern Japan

    Jun Suzuki, Ryoukichi Ikeda, Kengo Kato, Risako Kakuta, Yuta Kobayashi, Akira Ohkoshi, Ryo Ishii, Ai Hirano-Kawamoto, Jun Ohta, Rei Kawata, Tomonori Kanbayashi, Masaki Hatano, Tadahisa Shishido, Yuya Miyakura, Kento Ishigaki, Yasunari Yamauchi, Miho Nakazumi, Takuya Endo, Hiroki Tozuka, Shiori Kitaya, Yuki Numano, Shotaro Koizumi, Yutaro Saito, Mutsuki Unuma, Ken Hashimoto, Eiichi Ishida, Toshiaki Kikuchi, Takayuki Kudo, Kenichi Watanabe, Masaki Ogura, Masaru Tateda, Takatsuna Sasaki, Nobuo Ohta, Tatsuma Okazaki, Yukio Katori

    PLoS ONE　16　(7 July)　2021年7月

    DOI： 10.1371/journal.pone.0254261 　

    eISSN： 1932-6203

  5. 甲状腺の取扱いに配慮した食道癌集学的治療後のハイリスク下咽頭喉頭摘出術の一例(気管壊死症例との比較)

    石井亮, 大越明, 中山勇樹, 東賢二郎, 中目亜矢子, 岡本宏史, 谷山裕亮, 香取幸夫

    日本気管食道科学会総会ならびに学術講演会プログラム・予稿集　72nd　2021年

  6. 頭頸部再建手術における高齢者機能評価スクリーニングツール(G8)の合併症予測に対する有用性

    中山勇樹, 大越明, 石井亮, 中目亜矢子, 東賢二郎, 香取幸夫

    日本気管食道科学会総会ならびに学術講演会プログラム・予稿集　72nd　2021年

  7. 【カラーアトラス 口腔・咽頭粘膜疾患-目で見て覚える鑑別ポイント】咽頭粘膜の悪性腫瘍

    中山 勇樹, 小川 武則, 大越 明, 中目 亜矢子, 吉田 拓矢, 小泉 祥太郎, 香取 幸夫

    耳鼻咽喉科・頭頸部外科　92　(2)　152-160　2020年2月

    出版者・発行元： (株)医学書院

    ISSN： 0914-3491

    eISSN： 1882-1316

  8. 同時性四重複癌に対する複数診療科の連携による集学的治療

    江場 俊介, 野津田 泰嗣, 星 史彦, 大石 久, 松田 安史, 佐渡 哲, 野田 雅史, 桜田 晃, 西條 憲, 大越 明, 田中 直樹, 岡田 克典

    胸部外科　72　(9)　655-657　2019年9月

    出版者・発行元： (株)南江堂

    ISSN： 0021-5252

  9. p16陽性中咽頭癌の疫学的特徴

    石田英一, 石田英一, 中目亜矢子, 小川武則, 臼渕肇, 石川智彦, 大越明, 六郷正博, 香取幸夫

    日本頭頸部外科学会総会ならびに学術講演会プログラム・予稿集　29th　2019年

  10. 前頭洞癌に対して前頭蓋底手術を施行した一例

    六郷正博, 小川武則, 大越明, 中目亜矢子, 鈴木淳, 若盛隼, 吉田拓矢, 香取幸夫

    日本頭頸部外科学会総会ならびに学術講演会プログラム・予稿集　29th　2019年

  11. 下歯肉癌手術における下顎骨切除範囲と術後機能の検討

    小川武則, 大越明, 石田英一, 石井亮, 石川智彦, 宮下仁, 永井宏和, 佐藤奈央子, 小山重人, 高地崇, 高木尚之, 香取幸夫

    頭頸部癌　44　(2)　168-168　2018年5月9日

    出版者・発行元： (一社)日本頭頸部癌学会

    ISSN： 1349-5747

  12. 仙台医療センターにおける喉頭癌症例の検討

    池田 怜吉, 舘田 勝, 森田 真吉, 大越 明, 堀 亨, 橋本 省

    耳鼻咽喉科展望　60　(補冊1)　22-23　2017年6月

    出版者・発行元： 耳鼻咽喉科展望会

    ISSN： 0386-9687

    eISSN： 1883-6429

  13. 顎二腹筋再建による喉頭挙上術

    大越明, 小川武則, 嵯峨井俊, 中目亜矢子, 東賢二郎, 石井亮, 香取幸夫

    日本頭頸部外科学会総会ならびに学術講演会プログラム・予稿集　27th　2017年

  14. 当科における喉頭癌の臨床検討

    舘田 勝, 池田 怜吉, 森田 真吉, 大越 明, 橋本 省

    日本耳鼻咽喉科学会会報　118　(4)　505-505　2015年4月

    出版者・発行元： (一社)日本耳鼻咽喉科学会

    ISSN： 0030-6622

    eISSN： 1883-0854

  15. 糖尿病合併突発性難聴症例に対するプロスタグランジンE1(PGE1)の治療効果

    大越 明, 舘田 豊, 石井 亮, 太田 淳, 東 賢二郎, 本蔵 陽平, 高梨 芳崇, 牛来 茂樹

    日本耳鼻咽喉科学会会報　117　(4)　469-469　2014年4月

    出版者・発行元： (一社)日本耳鼻咽喉科学会

    ISSN： 0030-6622

    eISSN： 1883-0854

  16. 声門上に陥頓した有鈎義歯異物 気管チューブイントロデューサーによる気道確保が有効であった1症例

    日高 浩史, 大越 明, 鈴木 貴博, 小林 俊光

    耳鼻咽喉科臨床 補冊　(補冊135)　58-58　2013年7月

    出版者・発行元： 耳鼻咽喉科臨床学会

    ISSN： 0912-1870

    eISSN： 2185-1557

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 2

  1. 必須微量元素セレン欠乏に注目した急性感音難聴の病態解明

    大越 明

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research

    研究種目：Grant-in-Aid for Early-Career Scientists

    研究機関：Tohoku University

    2019年4月1日 ～ 2022年3月31日

    詳細を見る 詳細を閉じる

    本研究は、酸化ストレス防御に働く含セレン蛋白質に注目し、必須微量元素セレンの欠乏による感音難聴発症のメカニズムを明らかにし、 臨床応用につなげることを目的としたものである。 本研究は、マウス遺伝学による基礎研究と、耳毒性をもつ代表的薬剤シスプラチン投与をうける頭頸部がん患者における観察研究を併行して行なった。マウスにおいて音響暴露後にABRにて聴力評価した結果としては、低セレン餌の飼育のみでは、通常餌と比べてABRの値に有意な差は認められなかった。Nrf2欠失マウスを低セレン餌で飼育して、同様の検討をすすめているが、安定した結果が得られておらず、仮説の検証は途中である。

  2. Nrf2誘導剤による放射線粘膜炎の緩和効果の検討

    大越 明

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research

    研究種目：Grant-in-Aid for Young Scientists (B)

    研究機関：Tohoku University

    2016年4月1日 ～ 2019年3月31日

    詳細を見る 詳細を閉じる

    独自の遺伝子改変マウスを用いて、転写因子Nrf2が口腔粘膜における抗酸化酵素群および細胞増殖関連遺伝子群の発現を調整していることを確認した。また、Nrf2活性により粘膜肥厚が制御されていることが明らかになった。放射線による口腔粘膜炎の改善効果においては、Nrf2の変化における有意な改善効果は得られていないが、条件検討および数を増やす追加実験を行う予定である。